{"id":3882,"date":"2018-01-26T14:05:29","date_gmt":"2018-01-26T05:05:29","guid":{"rendered":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/contents\/?p=3882"},"modified":"2018-01-26T14:05:29","modified_gmt":"2018-01-26T05:05:29","slug":"2017%e5%b9%b4%e6%a5%ad%e7%b8%be%e3%80%80%e3%81%9d%e3%81%ae2","status":"publish","type":"post","link":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/%e7%a0%94%e7%a9%b6%e7%b4%b9%e4%bb%8b\/3882\/","title":{"rendered":"2017\u5e74\u696d\u7e3e\u3000\u305d\u306e2"},"content":{"rendered":"

2017\u5e74\u696d\u7e3e\u3000\u305d\u306e2
\n\u25a0\u3000\u5b66\u4f1a\u30fb\u7814\u7a76\u4f1a\u767a\u8868
\n\u56fd\u5185\u5b66\u4f1a\uff08\u5168\u56fd\uff09<\/a>
\n\u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09<\/a>
\n\u25a0 \u8b1b\u6f14<\/a>
\n\u25a0 \u7814\u7a76\u52a9\u6210<\/a>
\n\u25a0 \u53d7\u8cde<\/a>
\n\u8ad6\u6587\u3001\u56fd\u969b\u5b66\u4f1a\u767a\u8868\u306f2017\u5e74\u696d\u7e3e\u3000\u305d\u306e1<\/a>\u3092\u3054\u89a7\u4e0b\u3055\u3044\u3002
\n—————————
\n\u25a0<\/span> \u5b66\u4f1a\u767a\u8868(\u56fd\u5185)<\/strong>
\n<\/a>\u25cf<\/span> \u56fd\u5185\u5b66\u4f1a(\u5168\u56fd)<\/p>\n

    \n
  1. Ryo Ogawa, Tomoyuki Kido, Masashi Nakamura, Teruhito Kido, Teruhito Mochizuki. MR assessment of fetal lung development by lung signal intensities and lung volume measurements. \u7b2c76\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2017. 4, \u6a2a\u6d5c)<\/li>\n
  2. \u5c0f\u5ddd\u907c,\u3000\u57ce\u6238\u502b\u4e4b,\u3000\u4e2d\u6751\u58ee\u5fd7,\u3000\u5bae\u5185\u7b11\u9e97,\u3000\u6a2a\u4e95\u656c\u5f18,\u3000\u798f\u5c71\u76f4\u7d00, \u57ce\u6238\u8f1d\u4ec1, \u5009\u7530\u8056,\u3000\u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. Fallot\u56db\u5fb4\u75c7\u5fc3\u5185\u4fee\u5fa9\u8853\u5f8c\u306b\u304a\u3051\u308b\u80ba\u8840\u6d41\u8a55\u4fa1. \u7b2c84\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba1\u653e\u5c04\u7dda\u7814\u7a76\u4f1a (2017. 1, \u4e09\u91cd)<\/li>\n
  3. Ryo Ogawa, Tomoyuki Kido, Masashi Nakamura, Teruhito Kido, Teruhito Mochizuki.\u3000Feature-tracking in patients with myocardial infarction: comparison to tagged magnetic resonance and wall thickening. JSMRM2017 \u7b2c45\u56de\u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\u5927\u4f1a (2017. 9, \u6803\u6728)<\/li>\n
  4. \u5ddd\u53e3\u76f4\u4eba, \u7530\u4ee3\u3089\u307f, \u4e95\u4e0a\u6b66, \u4e09\u6728\u5747, \u4ed6. N-13 \u30a2\u30f3\u30e2\u30cb\u30a2 PET \u5b9a\u91cf\u5024\u306b\u304a\u3051\u308bMFR ratio\u306e\u865a\u8840\u6027\u75c5\u5909\u8a3a\u65ad\u80fd\u306e\u691c\u8a0e. \u7b2c27\u56de \u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a (2017.1, \u6d25)<\/li>\n
  5. \u5ddd\u53e3\u76f4\u4eba\u3001\u4ed6. Diagnostic performance of myocardial flow reserve ratio for the detection of obstructive coronary artery disease in 13N-ammonia PET. \u7b2c81\u56de \u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a (2017.3, \u91d1\u6ca2)<\/li>\n
  6. Kawaguchi N, Yoshida K, Tashiro R, Inoue T, Miki H, et al. Diagnostic performance of hybrid imaging on cardiac CT and 13N-ammonia PET for the detection of obstructive coronary artery disease. \u7b2c76\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2017.4, \u6a2a\u6d5c)<\/li>\n
  7. \u5ddd\u53e3\u76f4\u4eba\u3001\u77f3\u4e38\u826f\u5e83\u3001\u9ad8\u9580\u653f\u5609\u3001\u5409\u7530\u548c\u6a39\u3001\u6751\u4e0a\u5fe0\u53f8\u3001\u4e09\u6728\u5747\u3001\u798f\u5c71\u76f4\u7d00\u3001\u7530\u4e2d\u5b8f\u660e. \u5f53\u9662\u306b\u304a\u3051\u308b\u814e\u8840\u7ba1\u7b4b\u8102\u80aa\u816b\u306b\u5bfe\u3059\u308b\u52d5\u8108\u585e\u6813\u8853\u306e\u6cbb\u7642\u52b9\u679c\u306e\u691c\u8a0e. \u7b2c46\u56de \u65e5\u672cIVR\u5b66\u4f1a\u7dcf\u4f1a (2017.5, \u5ca1\u5c71)<\/li>\n
  8. \u5ddd\u53e3\u76f4\u4eba.\u3000Cardiovascular hybrid imaging <PET\/CT~\u5fc3\u7b4b\u8840\u6d41\u3068\u51a0\u52d5\u8108~\u30a2\u30f3\u30e2\u30cb\u30a2PET>. \u7b2c50\u56de \u5fc3\u81d3\u6838\u533b\u5b66\u61c7\u8a71\u4f1a \uff081 \u6771\u4eac\uff09<\/li>\n
  9. Kurata A, Uetani T, Nishimura K, Inoue K, Suzuki J, Ikeda S, Inoue Y, Ogimoto A, Kido T, Miyagawa M, MochizuiT. Quantification of the myocardial area at risk using coronary CT angiography and Voronoi algorithm-based myocardial segmentation in patients with acute myocardial infarction; a comparison with late gadolinium enhancement during cardiac magnetic resonance imaging. The 65th Annual Scientific Session of the Japanese College of Cardiology (2017, September. Osaka)<\/li>\n
  10. \u9ad8\u9580\u653f\u5609, \u4e09\u6728\u5747. \u4e2d\u67a2\u795e\u7d4c\u9650\u5c40\u6027\u8840\u7ba1\u708e\u306e1\u4f8b. \u7b2c37\u56de\u795e\u7d4c\u653e\u5c04\u7dda\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7. (2017.6, \u5c90\u961c)<\/li>\n
  11. \u9ad8\u7530\u7d00\u5b50\uff0c\u6ff1\u672c\u6cf0\uff0c\u77f3\u5ddd\u6d69\u53f2, \u9577\ufa11\u6167\uff0c\u795e\ufa11\u535a\u5145, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u7532\u72b6\u817a\u764c\u518d\u767a\u30fb\u8ee2\u79fb\u75c7\u4f8b\u306b\u5bfe\u3059\u308b\u653e\u5c04\u6027\u30e8\u30fc\u30c9\u5185\u7528\u7642\u6cd5\u306e\u6cbb\u7642\u6210\u7e3e\u306e\u691c\u8a0e. \u7b2c2\u56deSociety of Advanced Medical Imaging ((2016.7, \u5927\u962a)<\/li>\n
  12. \u9ad8\u7530\u7d00\u5b50\uff0c\u6ff1\u672c\u6cf0\uff0c\u77f3\u5ddd\u6d69\u53f2, \u9577\ufa11\u6167\uff0c\u795e\ufa11\u535a\u5145, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u7532\u72b6\u817a\u764c\u518d\u767a\u30fb\u8ee2\u79fb\u75c7\u4f8b\u306b\u5bfe\u3059\u308b\u653e\u5c04\u6027\u30e8\u30fc\u30c9\u5185\u7528\u7642\u6cd5\u306e\u6cbb\u7642\u6210\u7e3e\u306e\u691c\u8a0e. \u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u7b2c30\u56de\u5b66\u8853\u5927\u4f1a (2016.11, \u5927\u962a)<\/li>\n
  13. \u7af9\u53e3\u5d07, \u5ca9\u6751\u5353\u660e, \u539f\u4e95\u5ddd\u8c4a\u7ae0, \u6751\u7530\u771f\u592e, \u4e2d\u5cf6\u76f4\u7f8e, \u798f\u4e95\u8061\uff0e\u8179\u90e8\u9aa8\u76e4\u5916\u50b7\u306b\u5bfe\u3059\u308b\u7dca\u6025\u52d5\u8108\u585e\u6813\u8853\uff0e\u7b2c53\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a\uff082017\uff0e9\uff0c\u677e\u5c71\uff09<\/li>\n
  14. \u7530\u4e2d\u5b8f\u660e\u3001\u8840\u7ba1\u585e\u6813\u8853\u3092\u65bd\u884c\u3057\u305f\u7d4c\u76ae\u5185\u8996\u93e1\u7684\u80c3\u763b\u9020\u8a2d\u8853(PEG)\u306b\u4f34\u3046\u4e0a\u8179\u58c1\u52d5\u8108\u640d\u50b7\u306e1\u4f8b\u3001\u7b2c53\u56de\u65e5\u672c\u8179\u90e8\u6551\u6025\u5b66\u4f1a(2017.3\u3001\u6a2a\u6d5c\uff09<\/li>\n
  15. \u7530\u4e2d\u5b8f\u660e\u3001\u6d25\u7530\u5b5d\u6cbb\u3001\u671b\u6708\u8f1d\u4e00\u3001\u5927\u4e0b\u5b97\u4eae\u3001\u99ac\u8d8a\u5065\u4ecb\u3001\u5c0f\u5ddd\u6643\u5e73\u3001\u85e4\u5c71\u6cf0\u4e8c\u3001\u9ad8\u7530\u6cf0\u6b21.\u751f\u4f53\u809d\u79fb\u690d\u8853\u5f8c\u809d\u52d5\u8108\u7834\u88c2\u306b\u5bfe\u3057\u3066\u30b3\u30a4\u30eb\u585e\u6813\u8853\u3092\u65bd\u884c\u3057\u305f1\u4f8b\u3001\u7b2c46\u56de\u65e5\u672cIVR\u5b66\u4f1a\u7dcf\u4f1a(2017.5\u3001\u5ca1\u5c71\uff09<\/li>\n
  16. \u7530\u4e2d\u5b8f\u660e\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u671b\u6708\u8f1d\u4e00.\u80ba\u56a2\u80de\u5185\u306b\u5408\u4f75\u3057\u305f\u80baAVM\u306e1\u4f8b.\u7b2c2\u56deJapan Peripheral Embolization Conference(2017.10\u3001\u798f\u5ca1\uff09<\/li>\n
  17. \u7530\u4e2d\u5b8f\u660e\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u6d25\u7530\u5b5d\u6cbb\u3001\u671b\u6708\u8f1d\u4e00\u3001\u516b\u6749\u3000\u5de7.\u7dda\u7dad\u7b4b\u6027\u7570\u5f62\u6210\u306b\u5408\u4f75\u3057\u305f\u7834\u88c2\u814e\u52d5\u8108\u7624\u306b\u5bfe\u3057\u3066\u30b9\u30c6\u30f3\u30c8\u30b0\u30e9\u30d5\u30c8\u306b\u3066\u6cbb\u7642\u3057\u305f1\u4f8b\u3001\u7b2c58\u56de\u65e5\u672c\u8108\u7ba1\u5b66\u4f1a(2017.10\u3001\u6771\u4eac\uff09<\/li>\n
  18. \u7530\u4e2d\u5b8f\u660e.\u00a0\u30d0\u30a4\u30a2\u30d0\u30fc\u30f3\u306b\u3066\u6cbb\u7642\u3057\u305f\u7834\u88c2\u814e\u52d5\u8108\u7624\u306e1\u4f8b\u3001\u7b2c5\u56de\u6551\u6025\u30fb\u5916\u50b7IVR\u75c7\u4f8b\u691c\u8a0e\u4f1a(2017.12\u3001\u6771\u4eac\uff09<\/li>\n
  19. \u7530\u4e2d \u653f\u884c\u3001\u6771\u91ce \u535a\u3001\u5ddd\u6761 \u6587\u9686\u3001\u6c60\u6c34 \u6681\u5f66\u3001\u4e2d\u7530 \u8302\u3001\u4ed6. Step & Shoot\u6cd5\u3092\u7528\u3044\u305f\u6df1\u5438\u6c17\u606f\u6b62\u3081\u80ba\u8840\u6d41 \u7b2c37\u56de\u65e5\u672c\u6838\u533b\u5b66\u6280\u8853\u5b66\u4f1a\u7dcf\u4f1a\u5b66\u8853\u5927\u4f1a (2017. 10, \u6a2a\u6d5c\u5e02)<\/li>\n
  20. T Tsuda, M Matsuda, M Miyagawa, T Mochizuki, Y Mizuno, R Kitazawa, S Kitazawa, Y<\/sup> Relationship between Macroscopic Findings and 18<\/sup>F-FDG Uptake on PET\/CT in Gastrointestinal and Mesenteric Low-Grade Lymphoma. 2017.4 \u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff08\u6771\u4eac\uff09\u6559\u80b2\u5c55\u793a<\/li>\n
  21. Shintaro Tsuruoka, Masaaki Kataoka, Kotaro Uwatsu, Atsushi Nishikawa, Terukazu Mochizuki. Prognostic value of HER2 status in breast cancer patients with brain metastases. \u7b2c76\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff0e\uff08 4, \u6a2a\u6d5c\uff09<\/li>\n
  22. \u974d\u5ca1\u614e\u592a\u90ce\u3001\u7247\u5ca1\u6b63\u660e\u3001\u4e0a\u6d25\u5b5d\u592a\u90ce\u3001\u897f\u5ddd\u6566\u3001\u6ff1\u672c\u6cf0\u3001\u671b\u6708\u8f1d\u4e00\uff0e\u5b50\u5bae\u9838\u764c\u306b\u5bfe\u3059\u308b\u6839\u6cbb\u7684\u653e\u5c04\u7dda\u6cbb\u7642\u75c7\u4f8b\u306e\u30ea\u30f3\u30d1\u7bc0\u8ee2\u79fb\u518d\u767a\u306e\u691c\u8a0e\uff0e\u7b2c55\u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\uff0e\uff08 10, \u6a2a\u6d5c\uff09<\/li>\n
  23. \u974d\u5ca1\u614e\u592a\u90ce\u3001\u7247\u5ca1\u6b63\u660e\u3001\u4e0a\u6d25\u5b5d\u592a\u90ce\u3001\u897f\u5ddd\u6566\u3001\u6ff1\u672c\u6cf0\u3001\u671b\u6708\u8f1d\u4e00\uff0eStage\u2160\u98df\u9053\u764c\u306b\u5bfe\u3059\u308b\u653e\u5c04\u7dda\u6cbb\u7642\u6210\u7e3e\u306e\u691c\u8a0e\uff0e\u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\u7b2c30\u56de\u5b66\u8853\u5927\u4f1a\uff0e\uff08 11, \u5927\u962a\uff09<\/li>\n
  24. \u4e2d\u6751\u58ee\u5fd7\u3000\u75c7\u4f8b\uff1aIgG4\u95a2\u9023\u51a0\u52d5\u8108\u5468\u56f2\u708e\u306e\u4e00\u4f8b SCMR Japan (2017.7, \u6771\u4eac)<\/li>\n
  25. Nakamura M, Kido To, Watanabe K, Mochizuki T et al. Diagnostic capability for myocardial ischemia using compressed sensing ATP-stress perfusion CMR at 3 T: First results on single center study. \u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\u5927\u4f1a (2017.9, \u5b87\u90fd\u5bae)<\/li>\n
  26. \u9577\ufa11\u6167, , \u4e2d\u5cf6\u76f4\u7f8e, \u897f\u5cf6\u7d00\u5b50, \u795e\ufa11\u535a\u5145, \u6ff1\u672c\u6cf0,\u00a0\u671b\u6708\u8f1d\u4e00. \u982d\u9838\u90e8\u6241\u5e73\u4e0a\u76ae\u764c\u653e\u5c04\u7dda\u6cbb\u7642\u306b\u304a\u3051\u308bFDG-PET\/CT\u3092\u7528\u3044\u305f\u4e88\u5f8c\u4e88\u6e2c\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c76\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2017. 4, \u6771\u4eac\uff09<\/li>\n
  27. \u6ff1\u672c\u6cf0\uff0c\u795e\u5d0e\u535a\u5145\uff0c\u9577\ufa11\u6167\uff0c\u9ad8\u7530\u7d00\u5b50\uff0c\u672c\u7530\u5f18\u6587\uff0c\u671b\u6708\u8f1d\u4e00\uff0e\u80ba\u5b9a\u4f4d\u7167\u5c04D95\u51e6\u65b9\u306b\u304a\u3051\u308bTarget Contouring\u306e\u5f71\u97ff\uff0e\u7b2c30\u56de\u9ad8\u7cbe\u5ea6\u653e\u5c04\u7dda\u5916\u90e8\u7167\u5c04\u90e8\u4f1a\u5b66\u8853\u5927\u4f1a\uff08 3, \u4ed9\u53f0\uff09<\/li>\n
  28. Hamamoto Y, Kanzaki H, Nagasaki K, Takata N, Ugumori T, Hato N, Mochizuk T. Influence of delay of postoperative radiotherapy on treatment outcomes of head and neck squamous cell carcinoma. \u7b2c76\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a\uff08 4, \u6a2a\u6d5c\uff09<\/li>\n
  29. \u6ff1\u672c\u6cf0\uff0c\u9ad8\u7530\u7d00\u5b50\uff0c\u9577\u5d0e\u6167\uff0c\u77f3\u5ddd\u6d69\u53f2\uff0c\u795e\u5d0e\u535a\u5145\uff0c\u671b\u6708\u8f1d\u4e00\uff0e\u7532\u72b6\u817a\u764c\u306b\u5bfe\u3059\u308b\u5916\u7167\u5c04\u6cbb\u7642\u306e\u7d4c\u9a13\uff0e\u7b2c55\u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a\uff0810\uff0c\u6a2a\u6d5c\uff09<\/li>\n
  30. \u6ff1\u672c\u6cf0\uff0c\u795e\u5d0e\u535a\u5145\uff0c\u9577\u5d0e\u6167\uff0c\u9ad8\u7530\u7d00\u5b50\uff0c\u77f3\u5ddd\u6d69\u53f2\uff0c\u671b\u6708\u8f1d\u4e00\uff0e\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u3078\u306e\u8853\u524d\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u306e\u7d4c\u9a13\uff0e\u7b2c30\u56de\u65e5\u672c\u653e\u5c04\u7dda\u816b\u760d\u5b66\u4f1a\uff0811\uff0c\u5927\u962a\uff09<\/li>\n
  31. \u9e7f\u5cf6 \u6587\u3001\u6771\u91ce \u535a\u3001\u5bae\u7530 \u60a0\u91cc\u3001\u8c9e\u5fb3 \u307f\u3061\u3053\u3001\u5ddd\u6761 \u6587\u9686\u3001\u4ed6. \u30a2\u30c7\u30ce\u30b7\u30f3\u8ca0\u8377\u5fc3\u7b4b\u8840\u6d41\u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u306b\u304a\u3051\u308b\u5fc3\u62cd\u6570\u5897\u52a0\u53cd\u5fdc\u306e\u920d\u3044\u75c7\u4f8b\u306e\u81e8\u5e8a\u7684\u7279\u5fb4. \u7b2c57\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a(2017. 10, \u6a2a\u6d5c\u5e02)<\/li>\n
  32. \u5175\u982d\u670b\u5b50, \u67f3\u751f\u884c\u4f38, \u6cbc\u672c\u52f2\u7537, \u9db4\ufa11\u6b63\u52dd, \u4efb\u8aa0\u96f2, \u4e0a\u5d8b\u4e00\u81e3, \u5de5\u85e4\u6b63\u4fca, \u6751\u4e0a\u5353\u9053. \u809d\u52d5\u8108\u585e\u6813\u8853\u5f8c\u306e\u809d\u7d30\u80de\u764c\u5c40\u6240\u518d\u767a\u4e88\u6e2c\uff1a\u30e8\u30fc\u30c9\u5bc6\u5ea6\u753b\u50cf\u306b\u3088\u308b\u30ea\u30d4\u30aa\u30c9\u30fc\u30eb\u5b9a\u91cf. \u00a0\u7b2c75\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2017.4, \u6a2a\u6d5c)<\/li>\n
  33. \u5e73\u7530\u96c5\u662d,\u00a0\u5ca9\u91ce\u7965\u5b50,\u00a0\u53e4\u8c37\u91ce\u9756\u535a,\u00a0\u7530\u6751\u5468\u592a,\u00a0\u4e2d\u6751\u8aa0\u6cbb,\u00a0\u8d64\u5b97\u660e\u4e45,\u00a0\u6e21\u908a\u826f\u5e73. IVR\u5358\u72ec\u3067\u6cbb\u7642\u3067\u304d\u305f\u5916\u50b7\u6027\u8178\u9593\u819c\u640d\u50b7\u306e\u4e00\u4f8b. \u7b2c46\u56de\u65e5\u672cIVR\u5b66\u4f1a\u7dcf\u4f1a(2017. 5,\u00a0\u5ca1\u5c71)<\/li>\n
  34. \u5e73\u7530\u96c5\u662d,\u00a0\u5ca9\u91ce\u7965\u5b50,\u00a0\u6d66\u5ca1\u5927\u77e5,\u00a0\u4e2d\u6751\u8aa0\u6cbb,\u00a0\u8d64\u5b97\u660e\u4e45,\u00a0\u4ed6. \u30b7\u30fc\u30b9\u3092\u4f75\u7528\u3057\u305f\u7d4c\u76ae\u7684\u30c9\u30ec\u30ca\u30fc\u30b8\u304c\u594f\u529f\u3057\u305f\u58ca\u6b7b\u6027\u81b5\u708e\u5f8c\u306e\u771f\u83cc\u611f\u67d3\u6027\u00a0Walled-off necrosis\u00a0\u306e1\u4f8b.\u00a0\u7b2c3\u56de\u00a0\u65e5\u672c\u7a7f\u523a\u30c9\u30ec\u30ca\u30fc\u30b8\u7814\u7a76\u4f1a(2017. 6,\u00a0\u5927\u962a)<\/li>\n
  35. \u5e73\u585a\u7fa9\u5eb7\u3001\u5c71\u7530\u5553\u4e4b\u3001\u7532\u6590\u6210\u5f66\u3001\u8239\u6728\u7fd4\u3001\u671b\u6708\u8f1d\u4e00\uff0e\u8074\u795e\u7d4c\u816b\u760d\u75c7\u4f8b\u306b\u304a\u3051\u308bMRI\u3067\u306e\u5897\u5f37\u52b9\u679c\uff1a\u816b\u760d\u5897\u5927\u901f\u5ea6\u3001\u30b5\u30a4\u30ba\u3068\u306e\u95a2\u9023\u6027\uff0e\u7b2c46\u56de\u65e5\u672c\u795e\u7d4c\u653e\u5c04\u7dda\u5b66\u4f1a\uff08 2, \u6771\u4eac\uff09<\/li>\n
  36. \u5e73\u585a\u7fa9\u5eb7\uff0e\u5c0f\u5150Desmoplastic Infantile Astrocytoma\u306e\uff11\u4f8b\uff0e\u7b2c37\u56de\u795e\u7d4c\u653e\u5c04\u7dda\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\uff08 6, \u5c90\u961c\uff09<\/li>\n
  37. \u798f\u5c71\u76f4\u7d00\u3001\u5009\u7530\u8056\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u5ca1\u7530\u77e5\u4e45\u3001\u5bae\u5185\u7b11\u9e97\u3001\u6a2a\u4e95\u656c\u5f18\u3001\u5c0f\u5ddd\u907c\u3001\u7530\u908a\u88d5\u8cb4\u3001\u4e2d\u6751\u58ee\u5fd7\u3001\u57ce\u6238\u502b\u4e4b\u3001\u57ce\u6238\u8f1d\u4ec1\u3001\u5bae\u5ddd\u6b63\u7537\u3001\u671b\u6708\u8f1d\u4e00\uff0e\u5c0f\u5150\u5fc3\u81d3CT\u306b\u304a\u3051\u308b2\u76f8\u6ce8\u5165\u6cd5\u306e\u6709\u7528\u6027\u306b\u95a2\u3059\u308b\u691c\u8a0e\uff0e\u7b2c27\u56de\u753b\u50cf\u52d5\u614b\u5b66\u4f1a\uff08 1, \u6771\u4eac\uff09<\/li>\n
  38. \u798f\u5c71\u76f4\u7d00\u3001\u4e09\u6728\u5747\u3001\u6cb3\u5185\u5b5d\u7bc4\u3001\u5409\u7530\u548c\u6a39\u3001\u9ad8\u9580\u653f\u5609\u3001\u5bae\u672c\u52a0\u5948\u5b50\u3001\u80fd\u7530\u7d17\u4ee3\u3001\u68ee\u5343\u5c0b\u3001\u6751\u4e0a\u5fe0\u53f8\u3001\u677e\u6728\u5f18\u91cf\u3001\u77f3\u4e38\u826f\u5e83\u3001\u9ad9\u6a4b\u5fe0\u7ae0\u3001\u4e95\u4e0a\u6b66. 3T-MRA\u3092\u7528\u3044\u305f\u8133\u52d5\u8108\u7624\u306e\u5f62\u614b\u8a55\u4fa1. \u7b2c45\u56de\u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u4f1a\u5927\u4f1a\uff089,\u6803\u6728\uff09<\/li>\n
  39. \u8239\u6728\u7fd4,\u00a0\u5e73\u585a\u7fa9\u5eb7,\u00a0\u671b\u6708\u8f1d\u4e00.\u00a0\u8996\u795e\u7d4c\u8840\u7ba1\u5947\u5f62\u306e\uff11\u4f8b.\u00a0\u7b2c46\u00a0\u56de\u795e\u7d4c\u653e\u5c04\u7dda\u5b66\u4f1a(2017. 2,\u00a0\u6771\u4eac)<\/li>\n
  40. \u677e\u7530\u6075, \u6d25\u7530\u5b5d\u6cbb, \u7530\u4e2d\u5b8f\u660e,\u3000\u671b\u6708\u8f1d\u4e00. \u9ec4\u8272\u8089\u82bd\u816b\u6027\u8180\u80f1\u708e\u306e1\u4f8b\u3000\u7b2c31\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a.\uff08 6, \u65ed\u5ddd\uff09<\/li>\n
  41. \u677e\u7530\u6075, \u6d25\u7530\u5b5d\u6cbb, \u7530\u4e2d\u5b8f\u660e,\u3000\u671b\u6708\u8f1d\u4e00. \u80c3\u795e\u7d4c\u9798\u816b\u306e1\u4f8b\u7b2c31\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a.\uff08 6, \u65ed\u5ddd\uff09<\/li>\n
  42. \u4e09\u6728\u5747, \u5e73\u585a\u7fa9\u5eb7. 3T MRI\u306b\u304a\u3051\u308b32ch Head coil\u3092\u7528\u3044\u305f3D TOF MRA(\u6559\u80b2\u5c55\u793a). \u7b2c46\u56de\u65e5\u672c\u795e\u7d4c\u653e\u5c04\u7dda\u5b66\u4f1a(2017. 2, \u6771\u4eac)<\/li>\n
  43. \u6a2a\u4e95\u656c\u5f18, \u57ce\u6238\u8f1d\u4ec1, \u798f\u5c71\u76f4\u7d00, \u7530\u908a\u88d5\u8cb4, \u5bae\u5185\u7b11\u9e97, \u5c0f\u5ddd\u907c, \u4e2d\u6751\u58ee\u5fd7, \u57ce\u6238\u502b\u4e4b, \u5009\u7530\u8056, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. Dynamic CT Perfusion\u691c\u67fb\u306b\u304a\u3051\u308b\u5fc3\u7b4b\u8840\u6d41\u5b9a\u91cf\u8a55\u4fa1\u30d1\u30e9\u30e1\u30fc\u30bf\u30fc(CT-MBF)\u306b\u53ca\u307c\u3059\u89e3\u6790\u624b\u6cd5\u306e\u9055\u3044\u306b\u3088\u308b\u5f71\u97ff. \u7b2c27\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a (2017. 1, \u6d25)<\/li>\n
  44. \u6a2a\u4e95\u656c\u5f18, \u7530\u908a\u88d5\u8cb4, \u57ce\u6238\u8f1d\u4ec1, \u798f\u5c71\u76f4\u7d00, \u5ddd\u53e3\u76f4\u4eba, \u5009\u7530\u8056, \u5c0f\u5ddd\u907c, \u4e2d\u6751\u58ee\u5fd7, \u57ce\u6238\u502b\u4e4b, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. Effects of Under-sampling on Quantitative Parameters in Dynamic Myocardial CT Perfusion Imaging\uff1aComparison between Deconvolution and Maximum-slope method. \u7b2c76\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a (2017. 4, \u6a2a\u6d5c)<\/li>\n
  45. \u6a2a\u4e95\u656c\u5f18, \u57ce\u6238\u8f1d\u4ec1, \u5009\u7530\u8056, \u6e21\u90e8\u7b11\u9e97, \u5c0f\u5ddd\u907c, \u4e2d\u6751\u58ee\u5fd7, \u5ddd\u53e3\u76f4\u4eba, \u57ce\u6238\u502b\u4e4b, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u51a0\u52d5\u8108CT\u306b\u3088\u308b\u30ea\u30b9\u30af\u9818\u57df\u89e3\u6790\u3068\u30c0\u30a4\u30ca\u30df\u30c3\u30afCT\u306b\u3088\u308b\u5fc3\u7b4b\u8840\u6d41\u5b9a\u91cf\u8a55\u4fa1\u306e\u4f75\u7528\u306b\u95a2\u3059\u308b\u691c\u8a0e. SAMI2017 (2017. 7, \u5927\u962a)<\/li>\n
  46. \u6a2a\u4e95\u656c\u5f18, \u57ce\u6238\u8f1d\u4ec1, \u5ddd\u53e3\u76f4\u4eba, \u5009\u7530\u8056, \u4e2d\u5c3e\u7814\u4e00, \u6e21\u90e8\u7b11\u9e97, \u5c0f\u5ddd\u907c, \u4e2d\u6751\u58ee\u5fd7, \u57ce\u6238\u502b\u4e4b, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. \u8ca0\u8377\u30c0\u30a4\u30ca\u30df\u30c3\u30af\u5fc3\u7b4bCT Perfusion\u691c\u67fb\u306b\u3088\u308b\u5fc3\u7b4b\u8840\u6d41\u5b9a\u91cf\u8a55\u4fa1\u30d1\u30e9\u30e1\u30fc\u30bf\u30fc\uff08Perfused Capillary Blood Volume\uff09\u306e\u51a0\u52d5\u8108\u75c5\u5909\u8a3a\u65ad\u80fd\u306b\u95a2\u3059\u308b\u691c\u8a0e. \u7b2c11\u56deSCCT\u7814\u7a76\u4f1a (2017. 9, \u6771\u4eac)<\/li>\n
  47. \u5409\u7530\u548c\u6a39, \u5ddd\u53e3\u76f4\u4eba, \u7530\u4ee3\u3089\u307f, \u4e95\u4e0a\u6b66, \u6728\u4e0b\u5c06\u57ce, \u4e09\u6728\u5747. \u5de6\u5fc3\u5ba4 Incidental focal FDG uptake\u306e\u5f8c\u65b9\u8996\u7684\u691c\u8a0e. \u7b2c84\u56de\u65e5\u672c\u5fc3\u81d3\u653e\u5c04\u7dda\u7814\u7a76\u4f1a (2017.1, \u4e09\u91cd)Yoshida K, Kawaguchi N, Tashiro R, Murakami T, Ishimaru Y, Takahashi T, Inoue T, Miki H. \u00a0A retrospective study of incidental focal FDG uptake in the left ventricle. \u7b2c76\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u79d1\u5b66\u4f1a (2017.4, \u6a2a\u6d5c)<\/li>\n
  48. \u5409\u7530\u548c\u6a39, \u6751\u4e0a\u5fe0\u53f8, \u9ad8\u9580\u653f\u5609, \u798f\u5c71\u76f4\u7d00, \u77f3\u4e38\u826f\u5e83, \u4e95\u4e0a\u6b66, \u4e09\u6728\u5747. \u5de8\u5927\u814e\u52d5\u8108\u7624\u7834\u88c2\u306b\u5bfe\u3057\u3066\u814e\u52d5\u8108\u672c\u5e79\u306e\u30b3\u30a4\u30eb\u585e\u6813\u8853\u3092\u65bd\u884c\u3057\u305f2\u4f8b. \u7b2c27\u56de\u65e5\u672c\u6551\u6025\u653e\u5c04\u7dda\u7814\u7a76\u4f1a (2017.9, \u611b\u5a9b)<\/li>\n
  49. \u6e21\u90e8\u7b11\u9e97\uff0c\u5bae\u5ddd\u6b63\u7537\uff0c\u6a2a\u4e95\u656c\u5f18\uff0c\u5c0f\u5ddd\u907c\uff0c\u7530\u908a\u88d5\u8cb4\uff0c\u798f\u5c71\u76f4\u7d00\uff0c\u4e2d\u6751\u58ee\u5fd7\uff0c\u57ce\u6238\u8f1d\u4ec1\uff0c\u5009\u7530\u8056\uff0c\u671b\u6708\u8f1d\u4e00\uff0e\u5fc3\u81d3\u5c02\u7528\u534a\u5c0e\u4f53SPECT\u88c5\u7f6e\uff1aDNM530c\u3092\u7528\u3044\u305f\u5fc3\u7b4b\u8840\u6d41\u4e88\u5099\u80fd\u306e\u6e2c\u5b9a\uff0e\u7b2c27\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a(2017\uff0e1\uff0c\u6d25)<\/li>\n
  50. \u6e21\u90e8\u7b11\u9e97\uff0c\u5bae\u5ddd\u6b63\u7537\uff0c\u5e73\u4e95\u90a6\u660e\uff0c\u6a2a\u4e95\u656c\u5f18\uff0c\u5c0f\u5ddd\u907c\uff0c\u4e2d\u6751\u58ee\u5fd7\uff0c\u5ddd\u53e3\u76f4\u4eba\uff0c\u57ce\u6238\u502b\u4e4b\uff0c\u57ce\u6238\u8f1d\u4ec1\uff0c\u5009\u7530\u8056\uff0c\u671b\u6708\u8f1d\u4e00\uff0eIncremental value of myocardial perfusion reserve for detection of multi-vessel coronary artery disease with use of a cadmium-zinc-telluride SPECT\uff0e\u7b2c76\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a(2017\uff0e4\uff0c\u6a2a\u6d5c)<\/li>\n
  51. \u6e21\u90e8\u7b11\u9e97\uff0c\u5bae\u5ddd\u6b63\u7537\uff0c\u5e73\u4e95\u90a6\u660e\uff0c\u6a2a\u4e95\u656c\u5f18\uff0c\u5c0f\u5ddd\u907c\uff0c\u4e2d\u6751\u58ee\u5fd7\uff0c\u5ddd\u53e3\u76f4\u4eba\uff0c\u57ce\u6238\u502b\u4e4b\uff0c\u57ce\u6238\u8f1d\u4ec1\uff0c\u5009\u7530\u8056\uff0c\u671b\u6708\u8f1d\u4e00\uff0eF-18 FDG PET\/CT\u306b\u304a\u3051\u308b\u5fc3\u623f\u7d30\u52d5\u60a3\u8005\u306e\u5fc3\u96c6\u7a4d\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e\uff0e\u7b2c27\u56de\u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a(2017\uff0e6\uff0c\u6771\u4eac)<\/li>\n
  52. \u6e21\u90e8\u7b11\u9e97\uff0c\u5bae\u5ddd\u6b63\u7537\uff0c\u5e73\u4e95\u90a6\u660e\uff0c\u6a2a\u4e95\u656c\u5f18\uff0c\u5c0f\u5ddd\u907c\uff0c\u4e2d\u6751\u58ee\u5fd7\uff0c\u5ddd\u53e3\u76f4\u4eba\uff0c\u57ce\u6238\u502b\u4e4b\uff0c\u57ce\u6238\u8f1d\u4ec1\uff0c\u5009\u7530\u8056\uff0c\u671b\u6708\u8f1d\u4e00\uff0e\u5fc3\u623f\u7d30\u52d5\u60a3\u8005\u306b\u304a\u3051\u308bF-18 FDG\u5fc3\u96c6\u7a4d\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e\uff0e\u7b2c2\u56deAdvanced Medical Imaging \u7814\u7a76\u4f1a(2017\uff0e7\uff0c\u5927\u962a)<\/li>\n
  53. \u6e21\u90e8\u7b11\u9e97\uff0c\u5bae\u5ddd\u6b63\u7537\uff0c\u5e73\u4e95\u90a6\u660e\uff0c\u6a2a\u4e95\u656c\u5f18\uff0c\u5c0f\u5ddd\u907c\uff0c\u4e2d\u6751\u58ee\u5fd7\uff0c\u5ddd\u53e3\u76f4\u4eba\uff0c\u57ce\u6238\u502b\u4e4b\uff0c\u57ce\u6238\u8f1d\u4ec1\uff0c\u5009\u7530\u8056\uff0c\u671b\u6708\u8f1d\u4e00\uff0e\u5fc3\u623f\u7d30\u52d5\u60a3\u8005\u306b\u304a\u3051\u308bF-18 FDG\u5fc3\u96c6\u7a4d\u306b\u3064\u3044\u3066\u306e\u691c\u8a0e\uff0e\u7b2c57\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a(2017\uff0e10\uff0c\u6a2a\u6d5c)<\/li>\n
  54. \u6e21\u90e8\u7b11\u9e97\uff0c\u5bae\u5ddd\u6b63\u7537\uff0c\u5e73\u4e95\u90a6\u660e\uff0c\u6a2a\u4e95\u656c\u5f18\uff0c\u5c0f\u5ddd\u907c\uff0c\u4e2d\u6751\u58ee\u5fd7\uff0c\u5ddd\u53e3\u76f4\u4eba\uff0c\u57ce\u6238\u502b\u4e4b\uff0c\u57ce\u6238\u8f1d\u4ec1\uff0c\u5009\u7530\u8056\uff0c\u671b\u6708\u8f1d\u4e00\uff0eIgG4\u95a2\u9023\u51a0\u52d5\u8108\u5468\u56f2\u708e\u306e1\u4f8b\uff0e\u7b2c58\u56de\u65e5\u672c\u8108\u7ba1\u5b66\u4f1a\u7dcf\u4f1a(2017\uff0e10\uff0c\u540d\u53e4\u5c4b)<\/li>\n
  55. \u6a2a\u5c71\u3000\u9686\u3001\u85e4\u672c\u60a6\u5b50\u3001\u6a2a\u5c71\u8cb4\u7d00\u3001\u5742\u4e95\u7f8e\u4f73\u3001\u5927\u4e80\u771f\u4e00\u3001\u767d\u5c71\u88d5\u5b50\u3001\u7af9\u539f\u548c\u5b8f\u3001\u7247\u5ca1\u6b63\u660e. \u5b50\u5bae\u9838\u764c\u2162B\u671fCCRT\u4f8b\u306e\u518d\u767a\u30ea\u30b9\u30af\u56e0\u5b50 \u7b2c55\u56de\u65e5\u764c\u6cbb(2017,10, 20-22,\u6a2a\u6d5c)<\/li>\n
  56. \u4f0a\u85e4\u82b3\u7d00\u3001\u79cb\u5143\u54f2\u592b\u3001\u624b\u5cf6\u662d\u6a39\u3001\u7247\u5ca1\u6b63\u660e\u3001\u570b\u6b66\u76f4\u4fe1\u3001\u9ad8\u68a8\u4ee5\u7f8e\u3001\u4f50\u3005\u6728\u525b\u5fd7\u3001\u4f0a\u85e4\u96c5\u662d\u3001\u68ee\u8c37\u519d\u7693\u3001\u9f4b\u85e4\u5178\u7537, \u9ad8\u30ea\u30b9\u30afT1-T2\u4e0b\u90e8\u76f4\u8178\u764c\u306b\u5bfe\u3059\u308b\u5c40\u6240\u5207\u9664\u5f8c\u306e\u88dc\u52a9\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u306e\u81e8\u5e8a\u7b2cII\u76f8\u8a66\u9a13 \u7b2c30\u56deJASTRO (2017\/11\/17-19, \u5927\u962a)<\/li>\n
  57. \u592a\u7530 \u967d\u4ecb\u3001\u5c0f\u6797 \u96c5\u592b\u3001\u4f50\u3005\u6728 \u826f\u5e73\u3001\u5229\u5b89 \u9686\u53f2\u3001\u5409\u6751 \u901a\u592e\u3001\u842c \u7be4\u61b2\u3001\u6751\u4e0a \u7950\u53f8\u3001\u7247\u5ca1 \u6b63\u660e\u3001\u5c71\u4e2d \u7af9\u6625\u3001\u5168\u7530 \u8c9e\u5e79\u3001\u7530\u539f \u4fe1\u3001\u5207\u9664\u53ef\u80fd\u5c40\u6240\u9032\u884c\u982d\u9838\u90e8\u764c\u306b\u5bfe\u3059\u308bTPE\u5c0e\u5165\u5316\u5b66\u7642\u6cd5\u3068Cmab\u4f75\u7528\u653e\u5c04\u7dda\u6cbb\u7642\u306e\u7b2c2\u76f8\u8a66\u9a13\u3000\u7b2c30\u56deJASTRO (2017\/11\/17-19, \u5927\u962a)<\/li>\n
  58. \u5fb3\u6c38\u4f38\u5b50\uff0c\u5fb3\u5897\u660e\u6587\uff0c\u53ea\u4fe1\u7f8e\u7d00\uff0c\u7d30\u5ddd\u6d69\u5e73\uff0c\u6850\u5c71\u90c1\u5b50\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587\uff0c\u6a2a\u5c71\u8cb4\u7d00\uff0c\u7af9\u539f\u548c\u5b8f\uff0c\u5bfa\u672c\u5178\u5f18\uff0e\u7c98\u819c\u4e0b\u7b4b\u816b\u304c\u4f75\u5b58\u3057\u8853\u524d\u8a3a\u65ad\u304c\u56f0\u96e3\u3067\u3042\u3063\u305f\u5b50\u5bae\u4f53\u90e8\u7c98\u6db2\u817a\u764c\u306e1\u4f8b\uff0e\u7b2c31\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a (2017.6.30, \u65ed\u5ddd)<\/li>\n
  59. \u83c5\u539f\u656c\u6587\uff0c\u5fb3\u6c38\u4f38\u5b50\uff0c\u7d30\u5ddd\u6d69\u5e73\uff0c\u6850\u5c71\u90c1\u5b50\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u5742\u4e95\u7f8e\u4f73\uff0c\u6a2a\u5c71\u9686\uff0c\u7af9\u539f\u548c\u5b8f\uff0c\u5bfa\u672c\u5178\u5f18\uff0e\u5b50\u5bae\u4f53\u90e8\u6f3f\u6db2\u6027\u817a\u764c\u304c\u9838\u90e8\u3078\u9032\u5c55\u3057\u3001\u8089\u816b\u69d8\u5909\u5316\u3092\u751f\u3058\u305f\u764c\u8089\u816b\u306e1\u4f8b\uff0e\u7b2c31\u56de\u65e5\u672c\u8179\u90e8\u653e\u5c04\u7dda\u5b66\u4f1a (2017.6.30, \u65ed\u5ddd)<\/li>\n
  60. \u6e05\u6c34\u8f1d\u5f66\uff0c\u5c71\u672c\u96c4\u592a\uff0c\u7d30\u5ddd\u6d69\u5e73\uff0c\u5fb3\u6c38\u4f38\u5b50\uff0c\u6850\u5c71\u90c1\u5b50\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587\uff0c\u6a2a\u5c71\u8cb4\u7d00\uff0c\u7af9\u539f\u548c\u5b8f\uff0c\u5bfa\u672c\u5178\u5f18\uff0e\u8179\u819c\u64ad\u7a2e\u3092\u4f34\u3063\u305f\u5375\u5de3\u9846\u7c92\u819c\u7d30\u80de\u816b\u306e1\u4f8b\uff0eJSAWI2017, 18th Annual Symposium (2017.9.1, \u6de1\u8def)<\/li>\n
  61. \u85e4\u672c\u60a6\u5b50\uff0c\u6a2a\u5c71\u8cb4\u7d00\uff0c\u5742\u4e95\u7f8e\u4f73\uff0c\u5927\u4e80\u771f\u4e00\uff0c\u767d\u5c71\u88d5\u5b50\uff0c\u6a2a\u5c71\u9686\uff0c\u7af9\u539f\u548c\u5b8f\uff0c\u5fb3\u6c38\u4f38\u5b50\uff0c\u83c5\u539f\u656c\u6587\uff0c\u5bfa\u672c\u5178\u5f18\uff0e\u5b50\u5bae\u7b4b\u816b\u5408\u4f75\u306e\u305f\u3081\u8853\u524d\u753b\u50cf\u8a3a\u65ad\u306b\u82e6\u616e\u3057\u305f\u5b50\u5bae\u4f53\u90e8\u7c98\u6db2\u6027\u764c\uff0eJSAWI2017, 18th Annual Symposium (2017.9.1, \u6de1\u8def)<\/li>\n
  62. \u5c71\u672c\u96c4\u592a\uff0c\u7d30\u5ddd\u6d69\u5e73\uff0c\u83c5\u539f\u656c\u6587\uff0c\u5fb3\u5897\u660e\u6587\uff0c\u6749\u672c\u9f8d\u58eb\u90ce\uff0c\u5c71\u4e0b\u7d20\u5f18\uff0c\u897f\u6751\u7406\u6075\u5b50\uff0c\u5fb3\u5897\u660e\u6587\uff0e\u4f4e\u60aa\u6027\u5ea6\u80ce\u5150\u578b\u817a\u764c\u306e1\u4f8b\uff0e\u7b2c31\u56de\u80f8\u90e8\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff082017.9.8\uff0c\u677e\u5c71\uff09<\/li>\n
  63. \u5c71\u672c\u96c4\u592a\uff0c\u5fb3\u6c38\u4f38\u5b50\uff0c\u7d30\u5ddd\u6d69\u5e73\uff0c\u6850\u5c71\u90c1\u5b50\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587\uff0c\u6a4b\u672c\u9999\u91cc\uff0c\u9580\u7530\u4f38\u4e5f\uff0c\u5bfa\u672c\u5178\u5f18\uff0e\u9838\u90e8\u30ea\u30f3\u30d1\u7bc0\u8ee2\u79fb\u3092\u521d\u767a\u75c7\u72b6\u3068\u3057\u305f\u5589\u982d\u30ab\u30eb\u30c1\u30ce\u30a4\u30c9\u306e1\u4f8b\uff0e\u7b2c30\u56de\u982d\u9838\u90e8\u653e\u5c04\u7dda\u7814\u7a76\u4f1a\uff082017.9.9\uff0c\u677e\u5c71\uff09<\/li>\n
  64. \u5c71\u672c\u96c4\u592a\uff0c\u7d30\u5ddd\u6d69\u5e73\uff0c\u5fb3\u6c38\u4f38\u5b50\uff0c\u6850\u5c71\u90c1\u5b50\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587\uff0c\u5c71\u4e0b\u7d20\u5f18\uff0c\u5927\u7530\u8015\u53f8\uff0c\u5bfa\u672c\u5178\u5f18\uff0c\u897f\u6751\u7406\u6075\u5b50\uff0c\u5927\u8c37\u6cbb\u5f66\uff0c\u7530\u908a\u88d5\u8cb4\uff0e\u8457\u660e\u306aFDG\u9ad8\u96c6\u7a4d\u3092\u793a\u3057\uff0c\u8853\u5f8c\u809d\u8ee2\u79fb\u3092\u8d77\u3053\u3057\u305f\u80ba\u30ab\u30eb\u30c1\u30ce\u30a4\u30c9\u306e1\u4f8b\uff0e\u7b2c57\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff082017.10.5, \u6a2a\u6d5c\uff09<\/li>\n
  65. \u5fb3\u6c38\u4f38\u5b50\uff0c\u5c71\u672c\u96c4\u592a\uff0c\u7d30\u5ddd\u6d69\u5e73\uff0c\u6850\u5c71\u90c1\u5b50\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587\uff0c\u5409\u7530\u529f\uff0c\u5c71\u4e0b\u7d20\u5f18\uff0c\u9ad8\u7551\u6d69\u4e4b\uff0e FDG\u96c6\u7a4d\u3092\u793a\u3057\u77ed\u671f\u9593\u3067\u5897\u5927\u3057\u305fpure GGO\u306e1\u4f8b\uff0e\u7b2c57\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff082017.10.5, \u6a2a\u6d5c\uff09<\/li>\n
  66. \u5c0f\u91ce\u525b\u53f2\uff0c\u672c\u7530\u90a6\u5f66\uff0c\u4e0b\u4e95\u7766\u7537\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587\uff0e\u653e\u5c04\u7dda\u533b\u85ac\u54c1\u3092\u6295\u4e0e\u3055\u308c\u305f\u60a3\u8005\u306e\u63a5\u89e6\u5236\u9650\u306b\u95a2\u3059\u308b\u30de\u30cb\u30e5\u30a2\u30eb\u4f5c\u6210\u306b\u3064\u3044\u3066\uff0e\u7b2c57\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\uff082017.10.6, \u6a2a\u6d5c\uff09<\/li>\n<\/ol>\n

    <\/a>\u25cf<\/span> \u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09<\/p>\n

      \n
    1. \u77f3\u5ddd \u6d69\u53f2\u3001\u6ff1\u672c \u6cf0\u3001\u9577\u5d0e \u6167\u3001\u974d\u5ca1 \u614e\u592a\u90ce\u3001\u9ad8\u7530 \u7d00\u5b50\u3001\u7267\u7530 \u61b2\u53f8\u3001\u671b\u6708 \u8f1d\u4e00\uff0e\u5f53\u9662\u306b\u304a\u3051\u308b\u817a\u69d8\u56a2\u80de\u764c\u306e\u653e\u5c04\u7dda\u7642\u6cd5\u306e\u6cbb\u7642\u7d4c\u9a13\uff0e\u7b2c129\u56de\u65e5\u672c\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a(2017.12.\u5ca1\u5c71)<\/li>\n
    2. \u6d77\u8001\u539f\u308b\u3044, \u5ca1\u7530\u77e5\u4e45, \u7530\u4ee3\u3089\u307f, \u4e95\u4e0a\u7950\u99ac, \u68b6\u539f\u8aa0, \u677e\u7530\u5065, \u83ca\u6c60\u6075\u4e00. \u5b50\u5baePEComa\u306e\u4e00\u4f8b. \u7b2c128\u56de\u3000\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u3000\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a(2017. 6, \u5ca1\u5c71)<\/li>\n
    3. \u5ca1\u7530\u52a0\u5948\u5b50, \u9752\u91ce\u7965\u53f8. \u5f53\u9662\u306b\u304a\u3051\u308bB-RTO\u306e\u6cbb\u7642\u6210\u7e3e. \u7b2c129\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a(2017.12,\u00a0\u5ca1\u5c71)<\/li>\n
    4. \u5ca1\u7530\u77e5\u4e45,\u7530\u4ee3\u3089\u307f,\u6d77\u8001\u539f\u308b\u3044,\u4e95\u4e0a\u7950\u99ac,\u68b6\u539f\u8aa0,\u677e\u7530\u5065,\u83ca\u6c60\u6075\u4e00.\u5bd2\u51b7\u51dd\u96c6\u7d20\u75c7\u3092\u5408\u4f75\u3057\u305f\u80baMALT\u30ea\u30f3\u30d1\u816b\u306e\u4e00\u4f8b. \u7b2c129\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a.\uff0812, \u5ca1\u5c71\uff09<\/li>\n
    5. \u5c0f\u5ddd\u907c.\u3000\u80f8\u90e8\u9818\u57df\u306ePhase contrast cine MRI \u3057\u307e\u306a\u307f\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9 (2017.11,\u611b\u5a9b)<\/li>\n
    6. \u5ddd\u53e3\u76f4\u4eba. \u3053\u3046\u3044\u3046\u75c7\u4f8b\u3001\u3042\u306a\u305f\u306a\u3089\u3069\u3046\u64ae\u308b\uff1f. \u7b2c5\u56de Ehime Heart IMagE CT \u30cf\u30f3\u30ba\u30aa\u30f3 (2017.4, \u611b\u5a9b)<\/li>\n
    7. \u5ddd\u53e3\u76f4\u4eba, \u671b\u6708\u8f1d\u4e00\u3001\u4ed6. \u30a2\u30f3\u30e2\u30cb\u30a2 PET \u5b9a\u91cf\u5024\u3092\u7528\u3044\u305f relative CFR \u306b\u3088\u308b\u865a\u8840\u75c5\u5909\u8a3a\u65ad\u80fd\u306e\u691c\u8a0e. \u7b2c110\u56de \u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a \u4e2d\u56fd\u30fb\u56db\u56fd\u5408\u540c\u5730\u65b9\u4f1a (2017.6, \u9ad8\u77e5)<\/li>\n
    8. \u5ddd\u53e3\u76f4\u4eba\u3001\u7530\u4e2d\u5b8f\u660e\u3001\u9ad8\u9580\u653f\u5609\u3001\u5409\u7530\u548c\u6a39\u3001\u798f\u5c71\u76f4\u7d00\u3001\u6751\u4e0a\u5fe0\u53f8\u3001\u77f3\u4e38\u826f\u5e83\u3001\u671b\u6708\u8f1d\u4e00. \u80ba\u52d5\u9759\u8108\u5947\u5f62\u585e\u6813\u8853\u306e\u5468\u8853\u671f\u306b\u7121\u75c7\u5019\u6027\u306e\u5408\u4f75\u75c7\u3092\u6765\u3057\u305f2\u4f8b. \u7b2c31\u56de\u4e2d\u56db\u56fdIVR\u7814\u7a76\u4f1a (2017.9, \u5ca1\u5c71)<\/li>\n
    9. \u5ddd\u53e3\u76f4\u4eba\u3001\u7530\u4e2d\u5b8f\u660e. AZUR CX35\u306e\u4f7f\u7528\u7d4c\u9a13 <\u53f3\u5185\u8178\u9aa8\u52d5\u8108\u7624\u306b\u5bfe\u3057\u3066\u30b3\u30a4\u30eb\u585e\u6813\u8853\u3092\u884c\u3063\u305f1\u4f8b>. \u7b2c3\u56de\u56db\u56fdIVR\u30bb\u30df\u30ca\u30fc (2017.11 \u611b\u5a9b)<\/li>\n
    10. \u795e\u5d0e\u3000\u535a\u5145\uff0c\u7247\u5ca1\u3000\u6b63\u660e\uff0c\u4e0a\u6d25\u3000\u5b5d\u592a\u90ce\u3000\u98df\u9053\u764c\u8853\u5f8c\u306e\u30ea\u30f3\u30d1\u7bc0\u518d\u767a\u306b\u5bfe\u3059\u308b\u653e\u5c04\u7dda\u6cbb\u7642\u6210\u7e3e\u306e\u691c\u8a0e\u3000\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a\uff082017\/12\/9-10, \u5ca1\u5c71\uff09<\/li>\n
    11. Kurata A. (invited presentation). CT-FFR. The 53rd autumn assembly of the Japan Radiology Society, Matsuyama, Ehime, Japan September, 2017.<\/li>\n
    12. \u6cb3\u5185\u5b5d\u7bc4, \u5409\u7530\u548c\u6a39, \u9ad8\u9580\u653f\u5609, \u5bae\u672c\u52a0\u5948\u5b50, \u798f\u5c71\u76f4\u7d00, \u80fd\u7530\u7d17\u4ee3, \u68ee\u5343\u5c0b, \u6751\u4e0a\u5fe0\u53f8, \u677e\u6728\u5f18\u91cf, \u77f3\u4e38\u826f\u5e83, \u9ad8\u6a4b\u5fe0\u7ae0, \u4e95\u4e0a\u6b66, \u4e09\u6728\u5747. BCG\u63a5\u7a2e\u5f8c\u306e\u591a\u767a\u9aa8\u9ac4\u708e\u306e1\u4f8b. \u7b2c128\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a \u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a. (2017.6, \u5ca1\u5c71)<\/li>\n
    13. \u6cb3\u5185\u5b5d\u7bc4, \u77f3\u4e38\u826f\u5e83, \u798f\u5c71\u76f4\u7d00, \u5409\u7530\u548c\u6a39, \u9ad8\u9580\u653f\u5609, \u6751\u4e0a\u5fe0\u53f8, \u4e95\u4e0a\u6b66, \u4e09\u6728\u5747. Segmental arterial mediolysis(SAM)\u304c\u539f\u56e0\u3068\u8003\u3048\u3089\u308c\u305f\u8179\u8154\u5185\u51fa\u8840\u306b\u5bfe\u3057TAE\u3092\u65bd\u884c\u3057\u305f1\u4f8b. \u7b2c31\u56de\u4e2d\u56fd\u56db\u56fdIVR\u7814\u7a76\u4f1a. (2017.9, \u5ca1\u5c71)<\/li>\n
    14. \u9ad8\u9580\u653f\u5609, \u6cb3\u5185\u5b5d\u7bc4, \u5409\u7530\u548c\u6a39, \u5bae\u672c\u52a0\u5948\u5b50, \u798f\u5c71\u76f4\u7d00, \u80fd\u7530\u7d17\u4ee3, \u68ee\u5343\u5c0b, \u6751\u4e0a\u5fe0\u53f8, \u677e\u6728\u5f18\u91cf, \u77f3\u4e38\u826f\u5e83, \u6a4b\u5fe0\u7ae0, \u4e95\u4e0a\u6b66, \u4e09\u6728\u5747. \u4e0b\u984e\u9aa8\u539f\u767a\u5de8\u7d30\u80de\u6027\u4fee\u5fa9\u6027\u8089\u82bd\u816b\u306e1\u4f8b. \u7b2c128\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a \u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a. (2017.6, \u5ca1\u5c71)<\/li>\n
    15. \u9ad8\u9580\u653f\u5609, \u77f3\u4e38\u826f\u5e83, \u6cb3\u5185\u5b5d\u7bc4, \u5409\u7530\u548c\u6a39, \u798f\u5c71\u76f4\u7d00, \u5ddd\u53e3\u76f4\u4eba, \u6751\u4e0a\u5fe0\u53f8, \u4e95\u4e0a\u6b66, \u4e09\u6728\u5747. \u8179\u8154\u52d5\u8108\u8d77\u59cb\u90e8\u9589\u585e\u306b\u5408\u4f75\u3057\u305f\u4e0b\u81b5\u5341\u4e8c\u6307\u8178\u52d5\u8108\u7624\u306b\u5bfe\u3057\u3066\u30b3\u30a4\u30eb\u585e\u6813\u8853\u3092\u65bd\u884c\u3057\u305f2\u4f8b. \u7b2c31\u56de\u4e2d\u56fd\u56db\u56fdIVR\u7814\u7a76\u4f1a. (2016.9, \u5ca1\u5c71)<\/li>\n
    16. \u7530\u4e2d\u5b8f\u660e\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u6d25\u7530\u5b5d\u6cbb\u3001\u671b\u6708\u8f1d\u4e00\u3001\u516b\u6749\u3000\u5de7.\u5c3f\u7ba1\u52d5\u8108\u763b\u306b\u5bfe\u3059\u308b\u30b9\u30c6\u30f3\u30c8\u30b0\u30e9\u30d5\u30c8\u5185\u633f\u8853\u306e\u6cbb\u7642\u6210\u7e3e\u3001\u65e5\u672c\u8840\u7ba1\u5916\u79d1\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a\u7acb\u306148\u56de\u7dcf\u4f1a(2017.8\u3001\u677e\u5c71)<\/li>\n
    17. \u7530\u4e2d\u5b8f\u660e\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u6d25\u7530\u5b5d\u6cbb\u3001\u671b\u6708\u8f1d\u4e00.\u30b4\u30a2\u30d0\u30a4\u30a2\u30d0\u30fc\u30f3\u30b9\u30c6\u30f3\u30c8\u30b0\u30e9\u30d5\u30c8\u306e\u521d\u671f\u4f7f\u7528\u7d4c\u9a13\u3001\u7b2c31\u56de\u4e2d\u56fd\u56db\u56fdIVR\u7814\u7a76\u4f1a(2017.9\u3001\u5ca1\u5c71)<\/li>\n
    18. \u7530\u4e2d\u5b8f\u660e.IVR round Table Discussion \u30b3\u30a4\u30eb\u306b\u601d\u3046\u3001\u7b2c1\u56deIVR\/Round Table Discussion(2017.9\u3001\u5ca1\u5c71)<\/li>\n
    19. \u4e2d\u9808\u8cc0\u3000\u4f73\u592e\u91cc, \u677e\u7530\u3000\u6075, \u5ca1\u7530\u3000\u52a0\u5948\u5b50, \u8239\u6728\u3000\u7fd4, \u5e73\u585a\u3000\u7fa9\u5eb7, \u6d25\u7530\u3000\u5b5d\u6cbb, \u671b\u6708\u3000\u8f1d\u4e00. Dual-energy CT\u306b\u3088\u3063\u3066\u5f97\u3089\u308c\u305f\u4eee\u60f3\u5358\u8272\uff38\u7dda\u753b\u50cf\u306e\u4e73\u764c\u5c40\u6240\u8a3a\u65ad\u306b\u304a\u3051\u308b\u6709\u7528\u6027\u306e\u691c\u8a0e. \u7b2c128\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a.\uff08 6, \u5ca1\u5c71\uff09<\/li>\n
    20. \u5e73\u4e95\u90a6\u660e, \u7530\u4e2d\u5b8f\u660e, \u9752\u91ce\u7965\u53f8,\u4ed6. \u9580\u8108\u5927\u5faa\u74b0\u30b7\u30e3\u30f3\u30c8\u306b\u3088\u308b\u9ad8\u30a2\u30f3\u30e2\u30cb\u30a2\u8840\u75c7\u306b\u5bfe\u3057Amplatzer Vascular Plug\u3092\u7528\u3044\u305f\u585e\u6813\u8853\u3092\u65bd\u884c\u3057\u305f\u4e00\u4f8b. \u611b\u5a9bIVR\u7814\u7a76\u4f1a\uff082,\u611b\u5a9b\uff09<\/li>\n
    21. \u5e73\u585a\u7fa9\u5eb7\u3001\u5bae\u5ddd\u6b63\u7537\u3001\u671b\u6708\u8f1d\u4e00\u3001\u77f3\u6751\u96bc\u4eba\u3001\u5927\u897f\u606d\u5e73\uff0e\u5f53\u9662\u306b\u304a\u3051\u308b\u30c0\u30c3\u30c8\u30b9\u30ad\u30e3\u30f3\u306e\u73fe\u72b6\u3068\u7dda\u72b6\u4f53\u96c6\u7a4d\u306e\u50be\u5411\uff0e\u7b2c21\u56de\u611b\u5a9b\u8133SPECTPET\u7814\u7a76\u4f1a\uff08 10, \u611b\u5a9b\uff09<\/li>\n
    22. \u798f\u5c71\u76f4\u7d00\u3001\u4e95\u4e0a\u6b66\u3001\u5ddd\u53e3\u76f4\u4eba\u3001\u6cb3\u5185\u5b5d\u7bc4\u3001\u5409\u7530\u548c\u6a39\u3001\u9ad8\u9580\u653f\u5609\u3001\u5bae\u672c\u52a0\u5948\u5b50\u3001\u80fd\u7530\u7d17\u4ee3\u3001\u68ee\u5343\u5c0b\u3001\u6751\u4e0a\u5fe0\u53f8\u3001\u677e\u6728\u5f18\u91cf\u3001\u77f3\u4e38\u826f\u5e83\u3001\u9ad9\u6a4b\u5fe0\u7ae0\u3001\u5ca1\u5c71\u82f1\u6a39\u3001\u4e09\u6728\u5747. \u5fc3\u81d3CT\u3068\u30a2\u30f3\u30e2\u30cb\u30a2PET\u304c\u865a\u8840\u6027\u5fc3\u75be\u60a3\u306e\u8a3a\u65ad\u3068\u6cbb\u7642\u5f8c\u8a55\u4fa1\u306b\u6709\u7528\u3060\u3063\u305f\uff11\u4f8b.\u3000\u7b2c52\u56de\u65e5\u672c\u6838\u533b\u5b66\u5b66\u4f1a\u4e2d\u56fd\u56db\u56fd\u5730\u65b9\u4f1a\uff086,\u5ca1\u5c71\uff09<\/li>\n
    23. \u7267\u7530\u61b2\u4e8c\u3001\u6ff1\u672c\u6cf0\u3001\u77f3\u5ddd\u6d69\u53f2\u3001\u9ad8\u7530\u7d00\u5b50\u3001\u974d\u5ca1\u614e\u592a\u90ce\u3001\u9577\ufa11\u6167\u3001\u7fbd\u85e4\u76f4\u4eba\u3001\u671b\u6708\u8f1d\u4e00. \u901a\u5e38\u5206\u5272\u5916\u7167\u5c04\u306b\u3088\u308b\u8074\u795e\u7d4c\u816b\u760d\u306e\u6cbb\u7642\u6210\u7e3e. \u3000\u7b2c129\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a.\uff08 12, \u5ca1\u5c71\uff09<\/li>\n
    24. \u6a2a\u4e95\u656c\u5f18, \u7530\u908a\u88d5\u8cb4, \u57ce\u6238\u8f1d\u4ec1, \u798f\u5c71\u76f4\u7d00, \u5bae\u5185\u7b11\u9e97, \u5c0f\u5ddd\u907c, \u4e2d\u6751\u58ee\u5fd7, \u57ce\u6238\u502b\u4e4b, \u5009\u7530\u8056, \u5bae\u5ddd\u6b63\u7537, \u671b\u6708\u8f1d\u4e00. Dynamic CT perfusion\u691c\u67fb\u306b\u304a\u3051\u308b\u64ae\u5f71\u9593\u9694\u6642\u9593\u5ef6\u9577\u306e\u5fc3\u7b4b\u8840\u6d41\u5b9a\u91cf\u8a55\u4fa1\u306b\u53ca\u307c\u3059\u5f71\u97ff. \u7b2c36\u56de\u305b\u3068\u3046\u3061\u5fc3\u81d3CT\u30fbMR\u52c9\u5f37\u4f1a (2017. 3, \u611b\u5a9b)<\/li>\n
    25. \u5409\u7530\u548c\u6a39, \u4e95\u4e0a\u6b66, \u6cb3\u5185\u5b5d\u7bc4, \u9ad8\u9580\u653f\u5609, \u5bae\u672c\u52a0\u5948\u5b50, \u798f\u5c71\u76f4\u7d00, \u68ee\u5343\u5c0b, \u6751\u4e0a\u5fe0\u53f8, \u677e\u6728\u5f18\u91cf, \u77f3\u4e38\u826f\u5e83, \u9ad9\u6a4b\u5fe0\u7ae0, \u4e09\u6728\u5747, \u6cb3\ufa11\u79c0\u6a39. \u809d\u5185\u80c6\u7ba1\u6d78\u6f64\u3092\u4f34\u3046\u809d\u7d30\u80de\u764c\u306eCT\u6240\u898b\uff1a\u809d\u5185\u80c6\u7ba1\u764c\u3068\u6bd4\u8f03\u3057\u3066. \u7b2c129\u56de \u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a \u4e2d\u56fd\uff65\u56db\u56fd\u5730\u65b9\u4f1a (2017.12, \u5ca1\u5c71)<\/li>\n
    26. \u6cb3\u5185\u5b5d\u7bc4, \u7530\u4e2d\u5b8f\u660e, \u6d25\u7530\u5b5d\u6cbb, \u671b\u6708\u8f1d\u4e00. \u809d\u7d30\u80de\u764c\u751f\u4f53\u809d\u79fb\u690d\u5f8c\u306e\u809d\u5185\u8ee2\u79fb\u306b\u5bfe\u3057TACE,RFA\u3092\u65bd\u884c\u3057\u305f1\u4f8b. \u7b2c12\u56de\u611b\u5a9bIVR\u52c9\u5f37\u4f1a. (2017.2, \u611b\u5a9b)<\/li>\n
    27. \u6cb3\u5185\u5b5d\u7bc4, \u4e95\u4e0a\u6b66. \u672a\u5206\u5316\u80ce\u5150\u6027\u8089\u816b\u306e1\u4f8b. \u677e\u5c71\u653e\u5c04\u7dda\u79d1\u533b\u4f1a\u3000\u7b2c16\u56de\u4f8b\u4f1a. (2017.6, \u611b\u5a9b)<\/li>\n
    28. \u9ad8\u9580\u653f\u5609, \u4e95\u4e0a\u6b66. \u5916\u50b7\u5f8c\u8102\u80aa\u585e\u6813\u75c7\u5019\u7fa4\u306e\uff11\u4f8b. \u611b\u5a9b\u770c\u653e\u5c04\u7dda\u79d1\u533b\u4f1a \u7b2c146\u56de\u4f8b\u4f1a. (2017.1, \u611b\u5a9b)<\/li>\n
    29. \u9ad8\u9580\u653f\u5609, \u5ddd\u53e3\u76f4\u4eba, \u6751\u4e0a\u5fe0\u53f8, \u77f3\u4e38\u826f\u5e83, \u4e95\u4e0a\u6b66, \u4e09\u6728\u5747. \u8179\u8154\u52d5\u8108\u8d77\u59cb\u90e8\u9589\u585e\u306b\u5408\u4f75\u3057\u305f\u4e0b\u81b5\u5341\u4e8c\u6307\u8178\u52d5\u8108\u7624\u306b\u5bfe\u3057\u3066\u30b3\u30a4\u30eb\u585e\u6813\u8853\u3092\u65bd\u884c\u3057\u305f1\u4f8b. \u7b2c12\u56de\u611b\u5a9bIVR\u52c9\u5f37\u4f1a. (2017.2, \u611b\u5a9b)<\/li>\n
    30. \u9ad8\u9580\u653f\u5609, \u4e09\u6728\u5747. \u591a\u767a\u6027\u9aa8\u9ac4\u816b\u9ac4\u5916\u75c5\u5909\u306e1\u4f8b. \u7b2c9\u56de\u810a\u690e\uff65\u810a\u9ac4\u753b\u50cf\u30af\u30e9\u30d6. (2017.4, \u6771\u4eac)<\/li>\n
    31. \u9ad8\u9580\u653f\u5609, \u4e95\u4e0a\u6b66. \u4e2d\u795e\u7d4c\u75c7\u72b6\u3092\u5448\u3057\u305f\u518d\u767a\u6027\u591a\u767a\u8edf\u9aa8\u708e\u306e1\u4f8b. \u7b2c42\u56de\u611b\u5a9b\u6838\u533b\u5b66\u61c7\u8a71\u4f1a. (2017.10, \u611b\u5a9b)<\/li>\n
    32. \u5409\u7530\u548c\u6a39, \u5ddd\u53e3\u76f4\u4eba. \u4e9c\u6025\u6027\u5fc3\u7b4b\u708e\u306e\u4e00\u4f8b. \u677e\u5c71\u5e02\u653e\u5c04\u7dda\u79d1\u533b\u4f1a \u7b2c15\u56de\u4f8b\u4f1a (2017.2, \u611b\u5a9b)<\/li>\n
    33. \u5409\u7530\u548c\u6a39, \u9ad8\u9580\u653f\u5609, \u4e95\u4e0a\u6b66, \u4e09\u6728\u5747. \u591a\u767a\u6027\u9aa8\u9ac4\u816b\u306b\u767a\u751f\u3057\u305f\u810a\u67f1\u7ba1\u5185\u9ac4\u5916\u75c5\u5909. \u7b2c31\u56de\u611b\u5a9b\u653e\u5c04\u7dda\u79d1\u533b\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u8b1b\u6f14\u4f1a (2017.5, \u611b\u5a9b)<\/li>\n
    34. \u5409\u7530\u548c\u6a39, \u4e09\u6728\u5747. \u30b7\u30a7\u30fc\u30b0\u30ec\u30f3\u75c7\u5019\u7fa4\u306e\u4e2d\u67a2\u795e\u7d4c\u75c5\u5909\u306e\u4e00\u4f8b. \u677e\u5c71\u5e02\u653e\u5c04\u7dda\u79d1\u533b\u4f1a \u7b2c17\u56de\u4f8b\u4f1a (2017.8, \u611b\u5a9b)<\/li>\n
    35. \u5c71\u672c\u96c4\u592a\uff0c\u7d30\u5ddd\u6d69\u5e73\uff0c\u5fb3\u6c38\u4f38\u5b50\uff0c\u6850\u5c71\u90c1\u5b50\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587\uff0c\u6749\u539f\u9032\u4ecb\uff0c\u5bfa\u672c\u5178\u5f18\uff0e\u808b\u9aa8\u306b\u767a\u751f\u3057\u305f\u5de8\u7d30\u80de\u4fee\u5fa9\u6027\u8089\u82bd\u816b\u306e1\u4f8b\uff0e\u7b2c128\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082017.6.16, \u5ca1\u5c71\uff09<\/li>\n
    36. \u7d30\u5ddd\u6d69\u5e73\uff0c\u5c71\u672c\u96c4\u592a\uff0c\u5fb3\u6c38\u4f38\u5b50\uff0c\u6850\u5c71\u90c1\u5b50\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587\uff0c\u5927\u4e80\u771f\u4e00\uff0c\u767d\u5c71\u88d5\u5b50\uff0c\u6a2a\u5c71\u9686\uff0c\u7af9\u539f\u548c\u5b8f\uff0c\u5bfa\u672c\u5178\u5f18\uff0e\u5b50\u5bae\u8089\u816b\u306eFDG-PET\/CT\u6240\u898b\uff0e\u7b2c52\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082017.6.17, \u5ca1\u5c71\uff09<\/li>\n
    37. \u5c71\u672c\u96c4\u592a\uff0c\u7d30\u5ddd\u6d69\u5e73\uff0c\u5fb3\u6c38\u4f38\u5b50\uff0c\u6850\u5c71\u90c1\u5b50\uff0c\u6e05\u6c34\u8f1d\u5f66\uff0c\u9152\u4e95\u4f38\u4e5f\uff0c\u83c5\u539f\u656c\u6587\uff0c\u6a4b\u6839\u52dd\u7fa9\uff0c\u5bfa\u672c\u5178\u5f18\uff0eTubulocystic renal cell carcinoma\u306e1\u4f8b\uff0e\u7b2c129\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff082017.12.9, \u5ca1\u5c71\uff09<\/li>\n<\/ol>\n

      <\/a>\u25a0<\/span> \u8b1b\u6f14<\/strong><\/p>\n

        \n
      1. \u4e95\u4e0a \u6b66\uff0eFDG-PET Lugano\u5206\u985e\u306b\u3064\u3044\u3066\uff0e\u611b\u5a9bPET\u7814\u7a76\u4f1a(2017.1, \u611b\u5a9b)<\/li>\n
      2. \u5c0f\u5ddd\u907c. \u7b2c129\u56deJRS\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\u6559\u80b2\u30bb\u30df\u30ca\u30fc\u3000\u533b\u5b66\u7269\u7406. \u7b2c129\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u4e2d\u56fd\u30fb\u56db\u56fd\u5730\u65b9\u4f1a\uff0812, \u5ca1\u5c71\uff09<\/li>\n
      3. \u5ddd\u53e3\u76f4\u4eba. FDG-PET \u306b\u304a\u3051\u308b\u5de6\u5ba4\u5fc3\u7b4b\u3078\u306e\u5076\u767a\u7684\u5c40\u6240\u96c6\u7a4d\u306e\u610f\u7fa9.\u00a0 \u677e\u5c71\u5e02\u653e\u5c04\u7dda\u79d1\u533b\u4f1a\uff082 \u677e\u5c71\uff09<\/li>\n
      4. \u57ce\u6238\u8f1d\u4ec1. \u5fc3\u81d3CT\u306f\u62e1\u5f35\u80fd\u4e0d\u5168\u8a55\u4fa1\u306b\u6709\u7528\u304b. \u7b2c27\u56de\u65e5\u672c\u5fc3\u8840\u7ba1\u753b\u50cf\u52d5\u614b\u5b66\u4f1a\u3001\u7b2c84\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba1\u653e\u5c04\u7dda\u7814\u7a76\u4f1a.\uff08 1, \u6d25\uff09<\/li>\n
      5. \u57ce\u6238\u8f1d\u4ec1. FFR-CT\u6642\u4ee3\u306b\u304a\u3051\u308bPerfusion CT\u306e\u5f79\u5272. FRIENDS LIVE2017. \uff083, \u6771\u4eac\uff09<\/li>\n
      6. \u57ce\u6238\u8f1d\u4ec1. Recent Trends and Developments. The 11th<\/sup> Congress of Asian Society of Cardiovascular Imaging. \uff086, \u4eac\u90fd\uff09<\/li>\n
      7. \u57ce\u6238\u8f1d\u4ec1. Development and experience using new CT technology in diagnosis of ischemic heart disease. The 4th<\/sup> Korea-Japan MRA club Symposium. \uff086, Taegu\uff09<\/li>\n
      8. \u57ce\u6238\u8f1d\u4ec1. \u5fc3\u81d3CT\u306e\u65b0\u305f\u306a\u5c55\u671b\u301c\u6a5f\u80fd\u89e3\u6790\u3001\u6d41\u4f53\u89e3\u6790\u3001\u88ab\u66dd\u4f4e\u6e1b\u301c. \u7b2c2\u56de\u9999\u5dddCT\u6280\u8853\u7814\u7a76\u4f1a. \uff086, \u9ad8\u677e\uff09<\/li>\n
      9. \u57ce\u6238\u8f1d\u4ec1. \u5fc3\u81d3CT\u306e\u73fe\u72b6\u3068\u5c06\u6765\u5c55\u671b\u301c\u72ed\u7a84\u8a55\u4fa1\u30fb\u30d7\u30e9\u30fc\u30af\u8a55\u4fa1\u30fbFFR-CT\u30fbPerfusion CT\u301c. \u685c\u6a4b\u30cf\u30f3\u30ba\u30aa\u30f3\u30bb\u30df\u30ca\u30fc. \uff086, \u5927\u962a\uff09<\/li>\n
      10. \u57ce\u6238\u8f1d\u4ec1. Current situation of noninvasive ischemia evaluations ~CT perfusion~. The 26th<\/sup> Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics. \uff087, \u4eac\u90fd\uff09<\/li>\n
      11. \u57ce\u6238\u8f1d\u4ec1. \u5faa\u74b0\u5668\u30ec\u30dd\u30fc\u30c8\u3092\u66f8\u304f\u305f\u3081\u306b\u77e5\u3063\u3066\u304a\u304f\u3079\u304d\uff17\u306e\u30b3\u30c4\u301c\u30de\u30eb\u30c1\u30e2\u30c0\u30ea\u30c6\u30a3\u3092\u4f7f\u3044\u3053\u306a\u3059\u301c. JCR\u30df\u30c3\u30c9\u30b5\u30de\u30fc\u30bb\u30df\u30ca\u30fc \uff082017.7, \u795e\u6238\uff09<\/li>\n
      12. \u57ce\u6238\u8f1d\u4ec1. \u6025\u6027\u8179\u75c7\u3068\u865a\u8840\u6027\u5fc3\u75be\u60a3\u306eCT\u753b\u50cf\u8a3a\u65ad. \u7b2c57\u56de\u9020\u5f71\u7814\u7a76\u4f1a. \uff087, \u4eca\u6cbb\uff09<\/li>\n
      13. \u57ce\u6238\u8f1d\u4ec1. VINCENT\u3092\u6d3b\u7528\u3057\u305f\u5fc3\u81d3CT\u89e3\u6790\u301c\u51a0\u52d5\u8108CTA\u3001Perfusion CT\u301c. Fujifilm Medical Seminar 2017. \uff089, \u672d\u5e4c\uff09<\/li>\n
      14. \u57ce\u6238\u8f1d\u4ec1. \u533b\u7642\u73fe\u5834\u306eX\u7dda\u64ae\u5f71\u3084X\u7ddaCT\u304c\u4f7f\u3048\u308b\u7523\u696d\u9818\u57df. \u30d8\u30eb\u30b9\u30b1\u30a2\u7523\u696d\u80b2\u6210\u652f\u63f4\u4e8b\u696d \u7814\u4fee\u4f1a. \uff0810, \u677e\u5c71\uff09<\/li>\n
      15. \u57ce\u6238\u8f1d\u4ec1. 4D-CT\u304c\u5207\u308a\u62d3\u304f\u753b\u50cf\u8a3a\u65ad\u306e\u6700\u524d\u7dda. \u7b2c44\u56de\u65e5\u672c\u81e8\u5e8a\u30d0\u30a4\u30aa\u30e1\u30ab\u30cb\u30af\u30b9\u5b66\u4f1a. \uff0811, \u677e\u5c71\uff09\uff40\uff40<\/li>\n
      16. \u57ce\u6238\u8f1d\u4ec1. \u5fc3\u81d3CT\u3067\u865a\u8840\u3092\u8a3a\u308b\u301cPerfusion CT\u306e\u81e8\u5e8a\u6d3b\u7528\u301c. Kyoto New Generation Conference of Cardiology 2017. \uff0811, \u4eac\u90fd\uff09<\/li>\n
      17. \u57ce\u6238\u8f1d\u4ec1. Perfusion CT\u3067\u865a\u8840\u3092\u8a3a\u308b\u301c\u64ae\u5f71\u304b\u3089\u89e3\u6790\u306e\u5b9f\u969b\u301c. \u718a\u672c\u753b\u50cf\u8a3a\u65ad\u7814\u7a76\u4f1a. \uff0812, \u718a\u672c\uff09<\/li>\n
      18. \u57ce\u6238\u502b\u4e4b. \u5fc3\u81d3MRI\u3092\u81e8\u5e8a\u3067\u751f\u304b\u3059. \u7b2c40\u56de\u5bcc\u5c71PTCA\u7814\u7a76\u4f1a\uff08 5, \u5bcc\u5c71\uff09<\/li>\n
      19. \u57ce\u6238\u502b\u4e4b. Clinical application of compressed sensing in cardiac MRI. Korean Japan MR Angiography Symposium 2017\u3000\uff08 6, \u97d3\u56fd\uff09<\/li>\n
      20. \u57ce\u6238\u502b\u4e4b. Stress Perfusion Late Gadolinium Enhancement MRI. The 11th<\/sup> Congress of Asian Society of Cardiac Imaging \uff08 6, \u4eac\u90fd\uff09<\/li>\n
      21. \u57ce\u6238\u502b\u4e4b. CMR\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8: Plaque Imaging. SCMR Japan WG Seminar\uff08 7, \u6771\u4eac\uff09<\/li>\n
      22. \u57ce\u6238\u502b\u4e4b. Compressed sensing\u304c\u3082\u305f\u3089\u3059\u65b0\u305f\u306a\u5fc3\u81d3MRI\u306e\u53ef\u80fd\u6027. \u7b2c53\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a\uff08 9, \u611b\u5a9b\uff09<\/li>\n
      23. \u57ce\u6238\u502b\u4e4b. \u5fc3\u81d3MRI\u306b\u304a\u3051\u308b\u5727\u7e2e\u30bb\u30f3\u30b7\u30f3\u30b0\u306e\u81e8\u5e8a\u5fdc\u7528. \u7b2c45\u56de\u65e5\u672c\u78c1\u6c17\u5171\u9cf4\u533b\u5b66\u5927\u4f1a\uff08 9, \u6803\u6728\uff09<\/li>\n
      24. \u57ce\u6238\u502b\u4e4b. \u9020\u5f71\u5fc3\u81d3MRI\u306e\u57fa\u672c\u3068\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8. \u30d0\u30a4\u30a8\u30eb\u753b\u50cf\u8a3a\u65adWEB\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\uff08 10, \u5927\u962a\uff09<\/li>\n
      25. \u57ce\u6238\u502b\u4e4b. \u5fc3\u81d3MRI\u306e\u57fa\u672c\u3068\u8aad\u5f71. \u7b2c18\u56de\u677e\u5c71\u653e\u5c04\u7dda\u79d1\u533b\u4f1a\uff08 11, \u611b\u5a9b\uff09<\/li>\n
      26. \u57ce\u6238\u502b\u4e4b. \u865a\u8840\u6027\u5fc3\u75be\u60a3\u3092\u8a3a\u308b \u7b2c38\u56de\u611b\u5a9b\u5fc3\u81d3\u6838\u533b\u5b66\u8ac7\u8a71\u4f1a\uff082017. 11, \u611b\u5a9b\uff09<\/li>\n
      27. \u57ce\u6238\u502b\u4e4b. \u5faa\u74b0\u5668\u4f4e\u4fb5\u8972\u8a3a\u65ad\u3001\u4f4e\u4fb5\u8972\u6cbb\u7642\u3092\u6975\u3081\u308b \u7b2c111\u56de\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u4e2d\u56fd\u5730\u65b9\u4f1a\uff082017. 12, \u5ca1\u5c71\uff09<\/li>\n
      28. \u5009\u7530\u8056. CT \u3067\u306e\u5fc3\u7b4b\u306e\u753b\u50cf\u8a3a\u65ad. \u7b2c 9 \u56de \u4e5d\u5dde\u30fb\u5c71\u53e3\u5faa\u74b0\u5668\u753b\u50cf\u7814\u7a76\u4f1a\uff082017, 3\u6708, \u798f\u5ca1\uff09<\/li>\n
      29. \u5009\u7530\u8056. \u5fc3\u81d3\u8840\u7ba13\u6b21\u5143\u30e2\u30c7\u30eb\u6587\u732e\u30ec\u30d3\u30e5\u30fc. \u7b2c10\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba13\u6b21\u5143\u30e2\u30c7\u30eb\u7814\u7a76\u4f1a\u30bb\u30df\u30ca\u30fc\uff082017, 7\u6708, \u5927\u962a\uff09<\/li>\n
      30. \u5009\u7530\u8056. \u6d77\u5916\u7559\u5b66\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\u306f\uff1f An experience in Erasmus MC. \u7b2c 11 \u56de SCCT \u7814\u7a76\u4f1a\u3000\u6559\u80b2\u30bb\u30c3\u30b7\u30e7\u30f3\uff082017, 9\u6708\u3001\u6771\u4eac\uff09<\/li>\n
      31. \u5009\u7530\u3000\u8056. \u5fc3\u81d3\u8840\u7ba13\u6b21\u5143\u30e2\u30c7\u30eb\u6587\u732e\u30ec\u30d3\u30e5\u30fc. \u7b2c4\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba13\u6b21\u5143\u30e2\u30c7\u30eb\u7814\u7a76\u4f1a\u30bb\u30df\u30ca\u30fc\uff082017, 10\u6708, \u5927\u962a\uff09<\/li>\n
      32. \u5009\u7530\u3000\u8056. \u5fc3\u81d3\u8840\u7ba13\u6b21\u5143\u30e2\u30c7\u30eb\u6587\u732e\u30ec\u30d3\u30e5\u30fc. \u7b2c5\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba13\u6b21\u5143\u30e2\u30c7\u30eb\u7814\u7a76\u4f1a\u30bb\u30df\u30ca\u30fc\uff082017, 12\u6708, \u5927\u962a\uff09<\/li>\n
      33. \u5009\u7530\u3000\u8056.\u3000SOMATOM Force \u306e\u521d\u671f\u7d4c\u9a13. SIEMENS \u30e6\u30fc\u30b6\u30fc\u30df\u30fc\u30c6\u30a3\u30f3\u30b0\uff082016, 9\u6708\u3001\u611b\u5a9b\uff09<\/li>\n
      34. \u5009\u7530\u3000\u8056. \u5fc3\u81d3\u8840\u7ba13\u6b21\u5143\u30e2\u30c7\u30eb\u6587\u732e\u30ec\u30d3\u30e5\u30fc. \u7b2c7\u56de\u65e5\u672c\u5fc3\u81d3\u8840\u7ba13\u6b21\u5143\u30e2\u30c7\u30eb\u7814\u7a76\u4f1a\u30bb\u30df\u30ca\u30fc\uff082016, 12\u6708\u3001\u5927\u962a\uff09<\/li>\n
      35. \u6771\u91ce \u535a. \u301c\u865a\u8840\u6027\u5fc3\u75be\u60a3\u3092\u8a3a\u308b\u301c\u3010SPECT\u3011. \u7b2c38\u56de\u611b\u5a9b\u5fc3\u81d3\u6838\u533b\u5b66\u8ac7\u8a71\u4f1a. (2017. 11, \u677e\u5c71)<\/li>\n
      36. \u6771\u91ce \u535a. \u7dcf\u8ad6. \u7b2c11\u56de\u65e5\u672c\u5fc3\u81d3\u6838\u533b\u5b66\u4f1a \u4e2d\u56db\u56fd\u5730\u533a \u5730\u57df\u5225\u6559\u80b2\u7814\u4fee\u4f1a (2017. 9, \u5e83\u5cf6)<\/li>\n
      37. \u6771\u91ce \u535a. \u6559\u80b2\u8b1b\u6f146 \u6838\u533b\u5b661 \u5fc3\u81d3 \u5fc3\u81d3\u6838\u533b\u5b66\u306e\u679c\u305f\u3059\u5f79\u5272:\u51a0\u52d5\u8108\u75be\u60a3\u306b\u304a\u3051\u308b\u30ea\u30b9\u30af\u5c64\u5225\u5316. \u7b2c76\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1a. (2017. 4, \u6a2a\u6d5c)<\/li>\n
      38. \u798f\u5c71\u76f4\u7d00. 3T MRI\u306b\u304a\u3051\u308b32ch Head coil \u3092\u7528\u3044\u305f3D TOF MRA.\u3000\u611b\u5a9b\u653e\u5c04\u7dda\u79d1\u533b\u4f1a\u7b2c\uff11\uff14\uff17\u56de\u4f8b\u4f1a(2017.9, \u611b\u5a9b)<\/li>\n
      39. \u798f\u5c71\u76f4\u7d00. \u3053\u3053\u307e\u3067\u5206\u304b\u308b\uff01\u5fc3\u81d3\u3000\u533b\u7642\u9023\u643a\u61c7\u8a71\u4f1a (2017.10, \u611b\u5a9b)<\/li>\n
      40. \u5bae\u5ddd\u6b63\u7537.\u534a\u5c0e\u4f53SPECT\u306e \u7b2c41\u56de \u5357\u4e88\u5faa\u74b0\u5668\u753b\u50cf\u7814\u7a76 (2017.1.27, \u5b87\u548c\u5cf6)<\/li>\n
      41. \u5bae\u5ddd\u6b63\u7537. \u865a\u8840\u8a55\u4fa1\u306b\u304a\u3051\u308b\u30de\u30eb\u30c1\u30e2\u30c0\u30ea\u30c6\u30a3\u6d3b\u7528; \u534a\u5c0e\u4f53SPECT\u3092\u7528\u3044\u3066CFR\u3092\u6c42\u3081\u308b. \u7b2c42\u56de New Town Conference (2017.2.11, \u795e\u6238)<\/li>\n
      42. \u5bae\u5ddd\u6b63\u7537. \u534a\u5c0e\u4f53SPECT\u304c\u5faa\u74b0\u5668\u8a3a\u7642\u3092\u5909\u3048\u308b. \u201cOverview of the novel SPECT camera with CZT semiconductor detectors\u201d \u7b2c81\u56de \u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a (2017.3.17, \u91d1\u6ca2)<\/li>\n
      43. Miyagawa M, Tashiro R, Mochizuki T. Invited lecture; Quantitative analysis of myocardial FDG uptake by PET\/CT for detection and follow-up of cardiac sarcoidosis. 3rd<\/sup> Asian Nuclear Medicine Academic Forum 2017 (ANMAF) (2017.5.12, Shanghai, China)<\/li>\n
      44. \u5bae\u5ddd\u6b63\u7537. Discovery NM530c\u3092\u7528\u3044\u305f\u30c0\u30a4\u30ca\u30df\u30c3\u30af\u53ce\u96c6\u6cd5\u3068\u89e3\u6790\u6cd5. \u7b2c5\u56de \u534a\u5c0e\u4f53SPECT\u7814\u7a76\u4f1a (2017.6.3, \u540d\u53e4\u5c4b)<\/li>\n
      45. \u5bae\u5ddd\u6b63\u7537. Discovery NM530c\u3092\u7528\u3044\u305fMFR index\u6e2c\u5b9a\u3068\u81e8\u5e8a\u5fdc\u7528. \u7b2c13\u56de \u4e5d\u5dde\u5fc3\u81d3\u6838\u533b\u5b66\u7814\u7a76\u4f1a (2017.7.1, \u798f\u5ca1)<\/li>\n
      46. \u5bae\u5ddd\u6b63\u7537. F-18 FDG PET\u306b\u3088\u308b\u5fc3\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u8a3a\u65ad\u306e\u5b9f\u969b. 57\u56de\u65e5\u672c\u6838\u533b\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a (2017.10.7, \u6a2a\u6d5c\uff09<\/li>\n
      47. \u5bae\u5ddd\u6b63\u7537. PET, SPECT\u3092\u7528\u3044\u305f\u51a0\u8840\u6d41\u4e88\u5099\u80fd (CFR) \u6e2c\u5b9a\u306e\u6709\u7528\u6027. \u7b2c30\u56de\u5317\u6d77\u9053\u5fc3\u81d3\u6838\u533b\u5b66\u30d5\u30a9\u30fc\u30e9\u30e0 (2017.11.18, \u672d\u5e4c\uff09<\/li>\n
      48. \u5c71\u672c\u5c1a\u5e78\uff0e\u653e\u5c04\u7dda\u3001\u539f\u5b50\u529b\u707d\u5bb3\u306e\u57fa\u790e\u3068\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u306b\u3064\u3044\u3066\uff0e\u639b\u5ddd\u5e02\u539f\u5b50\u529b\u5e02\u6c11\u5b66\u7fd2\u4f1a\uff083\u3001\u639b\u5ddd\uff09<\/li>\n
      49. \u5c71\u672c\u5c1a\u5e78\uff0e\u539f\u5b50\u529b\u707d\u5bb3\u533b\u7642\u306e\u52d5\u5411\u3068\u4eac\u90fd\u306e\u73fe\u72b6\uff0e\u4eac\u90fd\u5927\u5b66\u88ab\u3070\u304f\u533b\u7642\u7814\u4fee\u4f1a\uff084\u3001\u4eac\u90fd\uff09<\/li>\n
      50. \u5c71\u672c\u5c1a\u5e78\uff0e\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u306e\u670d\u7528\u3068\u52b9\u679c\uff0e\u798f\u5ca1\u770c\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u914d\u5e03\u306b\u95a2\u3059\u308b\u7814\u4fee\u4f1a\uff084\u3001\u7cf8\u5cf6\uff09<\/li>\n
      51. \u5c71\u672c\u5c1a\u5e78\uff0e\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u306e\u670d\u7528\u3068\u52b9\u679c\uff0e\u798f\u5ca1\u770c\u5b89\u5b9a\u30e8\u30a6\u7d20\u5264\u914d\u5e03\u306b\u95a2\u3059\u308b\u7814\u4fee\u4f1a\uff085\u3001\u7cf8\u5cf6\uff09<\/li>\n
      52. \u5c71\u672c\u5c1a\u5e78\uff0e\u653e\u5c04\u7dda\u3092\u6b63\u3057\u304f\u6050\u308c\u308b\uff0e\u5c0f\u6a3d\u5e02\u7acb\u75c5\u9662\u6551\u6025\u30fb\u707d\u5bb3\u533b\u7642\u5553\u767a\u90e8\u4f1a\u4e3b\u50ac\u8b1b\u6f14\u4f1a\uff087\u3001\u5c0f\u6a3d\uff09<\/li>\n
      53. \u5c71\u672c\u5c1a\u5e78\uff0e\u75c5\u9662\u306b\u304a\u3051\u308b\u6c5a\u67d3\u50b7\u75c5\u8005\u306e\u5bfe\u5fdc\uff0e\u4eac\u90fd\u5927\u5b66\u88ab\u3070\u304f\u533b\u7642\u7814\u4fee\u4f1a\uff087\u3001\u4eac\u90fd\uff09<\/li>\n
      54. \u5c71\u672c\u5c1a\u5e78\uff0e\u653e\u5c04\u7dda\u306e\u304a\u306f\u306a\u3057\uff0e\u611b\u5a9b\u770c\u8eab\u306e\u56de\u308a\u306e\u653e\u5c04\u7dda\u6e2c\u5b9a\u4f53\u9a13\u6559\u5ba4\uff088\u3001\u65b0\u5c45\u6d5c\uff09<\/li>\n
      55. \u5c71\u672c\u5c1a\u5e78\uff0e\u7dca\u6025\u88ab\u3070\u304f\u533b\u7642\uff0f\u539f\u5b50\u529b\u707d\u5bb3\u533b\u7642\u306b\u5fc5\u8981\u306a\u77e5\u8b58\uff0e\u7b2c53\u56de\u306b\u65e5\u96a0\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a\u3000\u6559\u80b2\u8b1b\u6f14\uff089\u3001\u677e\u5c71\uff09<\/li>\n
      56. \u5c71\u672c\u5c1a\u5e78\uff0e\u653e\u5c04\u7dda\u4e8b\u6545\u30fb\u539f\u5b50\u529b\u707d\u5bb3\u306b\u3064\u3044\u3066\u77e5\u3063\u3066\u304a\u304f\u3079\u304d\u3053\u3068\uff0e\u653e\u5c04\u7dda\u7642\u6cd5\u306e\u63a8\u9032\u306b\u95a2\u3059\u308b\u7814\u4fee\u4f1a\uff089\u3001\u5b87\u548c\u5cf6\uff09<\/li>\n
      57. \u5c71\u672c\u5c1a\u5e78\uff0e\u539f\u5b50\u529b\u707d\u5bb3\u6642\u306e\u653e\u5c04\u7dda\u6e2c\u5b9a\uff0e\u4eac\u90fd\u5927\u5b66\u88ab\u3070\u304f\u533b\u7642\u7814\u4fee\u4f1a\uff0812\u3001\u4eac\u90fd\uff09<\/li>\n
      58. \u5c71\u672c\u5c1a\u5e78\uff0eRadiation emergency medicine in Japan and the act of NSRA\uff0e\u5e83\u5cf6\u5927\u5b66\u30d5\u30a7\u30cb\u30c3\u30af\u30b9\u30d7\u30ed\u30b0\u30e9\u30e0\uff0812\u3001\u5e83\u5cf6\uff09<\/li>\n
      59. \u83c5\u539f\u656c\u6587\uff0e\u4e73\u764c\u8a3a\u7642\u306b\u304a\u3051\u308bPET\/CT\u306e\u6709\u7528\u6027\u3068\u5b9a\u91cf\u6307\u6a19\uff0e\u7b2c25\u56de\u65e5\u672c\u4e73\u764c\u5b66\u4f1a\u3000\u30e9\u30f3\u30c1\u30e7\u30f3\u30bb\u30df\u30ca\u30fc13\uff082017.7.14, \u798f\u5ca1\uff09<\/li>\n
      60. \u83c5\u539f\u656c\u6587\uff0e\u4e73\u764c\u8a3a\u7642\u306b\u304a\u3051\u308bFDG-PET\/CT\u306e\u6709\u7528\u6027\u3068\u30d4\u30c3\u30c8\u30d5\u30a9\u30fc\u30eb\uff0e\u7b2c74\u56de\u9ad8\u77e5\u770c\u6838\u533b\u5b66\u75c7\u4f8b\u691c\u8a0e\u4f1a\u3000\u7279\u5225\u8b1b\u6f14\uff082017.8.4, \u9ad8\u77e5\uff09<\/li>\n<\/ol>\n

        <\/a>\u25a0<\/span> \u7814\u7a76\u52a9\u6210<\/strong><\/p>\n

          \n
        1. \u5009\u7530\u3000\u8056. \u79d1\u7814\u57fa\u76e4C\u3000\uff082015-2017\uff09<\/li>\n
        2. \u5175\u982d\u670b\u5b50. \u6587\u90e8\u79d1\u5b66\u7701\u79d1\u5b66\u7814\u7a76\u8cbb\u88dc\u52a9\u91d1\u30002016\u5e744\u67081\u65e5\uff5e2019\u5e743\u670831\u65e5 \u57fa\u76e4\u7814\u7a76 (C) \u8ab2\u984c\u756a\u53f716K10369\u809d\u52d5\u8108\u5316\u5b66\u585e\u6813\u7642\u6cd5\u306b\u304a\u3051\u308b\u30c7\u30e5\u30a2\u30eb\u30a8\u30ca\u30b8\u30fc\uff23\uff34\u3092\u7528\u3044\u305f\u5b9a\u91cf\u7684\u6cbb\u7642\u52b9\u679c\u5224\u5b9a<\/li>\n<\/ol>\n

          <\/a>\u25a0<\/span> \u53d7\u8cde<\/strong><\/p>\n

            \n
          1. \u7af9\u53e3\u5d07\uff0e\u7b2c53\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u79cb\u5b63\u81e8\u5e8a\u5927\u4f1a \u512a\u79c0\u30dd\u30b9\u30bf\u30fc\u8cde(Bronze Medal)<\/li>\n
          2. \u6e21\u90e8\u7b11\u9e97. \u7b2c76\u56de\u65e5\u672c\u533b\u5b66\u653e\u5c04\u7dda\u5b66\u4f1a\u7dcf\u4f1aCypos\u8cde Platinum\u00a0Medal<\/li>\n
          3. \u5009\u7530\u3000\u8056. European Radiology, Peer Review Certificate<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

            2017\u5e74\u696d\u7e3e\u3000\u305d\u306e2 \u25a0\u3000\u5b66\u4f1a\u30fb\u7814\u7a76\u4f1a\u767a\u8868 \u56fd\u5185\u5b66\u4f1a\uff08\u5168\u56fd\uff09 \u56fd\u5185\u5b66\u4f1a\uff08\u5730\u65b9\u4f1a\uff09 \u25a0 \u8b1b\u6f14 \u25a0 \u7814\u7a76\u52a9\u6210 \u25a0 \u53d7\u8cde \u8ad6\u6587\u3001\u56fd\u969b\u5b66\u4f1a\u767a\u8868\u306f2017\u5e74\u696d\u7e3e\u3000\u305d\u306e1\u3092\u3054\u89a7\u4e0b\u3055\u3044\u3002 ———& […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-3882","post","type-post","status-publish","format-standard","hentry","category-20"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/posts\/3882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/comments?post=3882"}],"version-history":[{"count":0,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/posts\/3882\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/media?parent=3882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/categories?post=3882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.m.ehime-u.ac.jp\/school\/radiology\/wp-json\/wp\/v2\/tags?post=3882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}